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ABSTRACT
The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) comprise
four related molecules GDNF, neurturin (NRTN), persephin (PSPN) and artemin (ARTN)
that support the survival of many neurons in vitro and show different biological actions on
distinct neuronal populations in vivo. Outside the nervous system, GDNF is crucial for the
development of the embryonic kidney. SecretedGFLs activate the transmembrane tyrosine
kinase receptor RET through a GPI-linked co-receptor GFRá. GDNF binds preferentially
to GFRá1, NRTN to GFRá2, ARTN to GFRá3 and PSPN to chicken GFRá4. Activating
mutations in the RET gene cause tumors in organs of neuroendocrine origin such as the
human medullary thyroid and adrenal medulla. Inactivating mutations in RET are associated
with Hirschsprung´s disease or congenital megacolon.
In this work, we have characterized the mouse and human GFRα4 receptor that,
upon PSPN binding activates Ret. In mouse, Gfra4 is predominantly expressed in endocrine
organs, namely the thyroid, adrenal and pituitary glands. Tissue specific alternative splicing
of the mouse Gfra4 gene produces functional GPI-anchored GFRá4 isoforms mainly in
juvenile thyroid gland. In human, GFRA4 is expressed together with RET in thyroid
calcitonin producing C-cells, and in medullary thyroid carcinomas (MTC) originating
from C-cells. This suggests that GFRá4 may be involved in the pathogenesis of MTC, as
expression of other GFRá-receptors is absent in these tumors.
We generated GFRα4-deficient (-/-) mice which are viable and fertile and show no
obvious defects in the nervous system or other organs. However, although the number of
C-cells is normal in Gfra4-/- mice compared to wild-type littermates, calcitonin production
is significantly reduced in young but not adult Gfra4-/- mice compared to wild-type
littermates. It has been shown that extracellular calcium affects intracellular pathways
leading to calcitonin production by activating G-protein coupled Ca-sensing receptor in
C-cells. Thus, GFRá4/Ret signaling may be important for calcitonin production possibly
through the Ca-sensing receptor. Calcitonin is used therapeutically to treat diseases, such
as osteoporosis, characterized by increased bone resorption. As the functional GFRá4
continues to be expressed in adult human C-cells, GFRá4 may be relevant in osteoporosis.
GDNF is produced by Sertoli cells, and its receptors GFRá1 and Ret by spermatogonia
in the testis. To investigate the roles for GDNF in the testis, we produced transgenic mice
overexpressing GDNF specifically in testis. We also analyzed spermatogenesis in testes
from heterozygous GDNF-deficient mice. Overexpression of GDNF favored self-renewal
of spermatogenic stem cells resulting in depletion of spermatids, whereas low dosage of
GDNF in GDNF+/- mice resulted in depletion of undifferentiated stem cells. Therefore
we concluded that the GDNF dosage in testis is crucial for the regulation of cell fate
decision of undifferentiating spermatogonia. The heterozygous GDNF-deficient and
overexpressing transgenic mouse lines may thus serve as useful tools for studying the
pathogenesis of male infertility. Furthermore, signaling pathways activated by GDNF
may act as potential targets for developing male contraceptives.
Key words: GFRá4, GDNF, PSPN, Ret, thyroid, MTC, calcitonin, testis, spermatogenesis
11. REVIEW OF THE LITERATURE
1.1 Introduction to neurotrophic
factors
The development of the nervous system
is a complex process involving numerous
proteins implicated in cell fate decision
of neural progenitors, migration of neural
crest cells to proper targets and axonal
guidance etc. The ectodermally derived
neural tube forms the central nervous
system, including the brain, the spinal
cord, motor neurons and the neural
pituitary in the developing embryo.
Neural crest cells are derived from the
embryonic dorsal-most part of the neural
tube. Following epithelial to
mesenchymal transition the neural crest
cells migrate to their destined places in
the developing embryo to generate the
peripheral nervous system (PNS), facial
cartilage and bone, dentine of teeth,
melanocytes in the skin, connective and
smooth muscle tissue of large arteries
from the heart, neuroendocrine cells such
as chromaffin cells of the adrenal medulla
and thyroid parafollicular cells (C-cells)
and enteric neural cells (Gilbert, 2003).
The fate of the precursor neural crest cells
is in large determined by the cues of the
environment and soluble factors secreted
at their potential targets. The eventual
location of the neural crest precursor cell
is largely determining the fate of the cell.
After commitment to a neuronal fate, the
neuron ceases to divide and differentiate
through axonal outgrowth to specif ic
targets, and formation of synaptic
connections, finally undergoing a period
of programmed cell death.
Neurotrophic factors control several
vitally important functions in the nervous
system, both during development and in
the mature brain. The most important and
best studied roles of the neurotrophic
factors are the control of neuronal number
and stimulation of neurite growth, the
functions through which they were
initially discovered. In the development
of almost every neuronal population,
there is a period of programmed death,
during which a significant portion of the
initially generated neurons die (reviewed
by Oppenheim, 1991). Thus, in most
regions of the nervous system, the
neurons are initially overproduced, but
during the period of programmed death,
the number is reduced to correspond to
the actual requirement of a given tissue.
20-80% of the initial neurons die during
the programmed death period,
corresponding generally to the time of
target field innervation. In fact, during the
programmed death period, the target
tissues control their own innervation
density by regulating the number of
surviving neurons,  especially in the
peripheral nervous system (sympathetic
and sensory ganglia), but also in the
motor neurons. The neurons are basically
apoptotic during programmed death
period and tend to commit suicide by
default. Neurotrophic factors, produced
from target tissues, neutralize the
apoptotic program, thereby rescuing the
neurons from death. By the current target-
derived neurotrophic factor model
(Barde, 1989), the target tissues produce
neurotrophic factors in limiting amounts
that are suff icient to support only a
fraction of the neurons seeking to
innervate the tissue, whereas the neurons
remaining without neurotrophic support,
die by default. Thus, by producing
suitable levels of neurotrophic factors, the
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2tissues maintain alive only that number of
neurons that is required for their
innervation (reviewed by Davies, 2003;
Huang and Reichardt, 2001).
Neurotrophic factors secreted by target
tissues, bind to their receptors on the
nerve terminals, are endocytosed and
carried to the somae (reviewed by
Campenot and MacInnis, 2004), where
they actively block the ongoing apoptotic
program. The activated receptors trigger
survival pathways and suppress various
pro-apoptotic proteins (c-Jun, Bax, Bim,
DP5 etc.) (reviewed by Kaplan and Miller,
2000; Putcha and Johnson, 2004).
Different neurotrophic factors support
survival of distinct, but partially
overlapping populations of peripheral
neurons,  in addition to motor neurons
(reviewed by Henderson et al., 1998). The
importance of neurotrophic factors in the
control of neuronal number is best proven
in knockout mice of neurotrophins or
their receptors, where the main phenotype
was mostly the death of expected
populations of peripheral ganglion
neurons during the programmed death
period (reviewed by Snider, 1994).
Neurotrophic factors are indeed
important in the induction and guidance
of (at least) peripheral axons. In the
central nervous system, the survival-
promoting and neuritogenic functions of
neurotrophic factors are not as obvious as
in the peripheral ganglia, as evidenced by
essentially mild brain phenotypes in the
knockout mice (Snider, 1994). Thus, in
the brain, neurotrophic factors appear to
be involved in the differentiation and
functional modulation of the neurons,
rather than in survival. Indeed,
neurotrophins have been shown to have
both acute effects on synaptic
transmission and plasticity, and long-term
effects on synapse formation and function
(reviewed by Lu, 2003) and have been
shown to be important in the
pathophysiology of mood disorders
including major depressive disorder and
bipolar disorder (reviewed by Hashimoto
et al., 2004). Thus, neurotrophic factors
seem to have a role in all main functions
of the nervous system. Recent detailed in
vitro and in vivo investigations have
revealed important additional functions
for neurotrophic factors in non-neural
tissues and diseases (reviewed by Sariola,
2001).
Three families of polypeptides namely
the neurotrophins, the neurokines and the
glial cell line-derived neurotrophic factor
(GDNF) family ligands (GFLs) are
traditionally classified as neurotrophic
factors because they were initially
described as factors acting on neuronal
survival and growth. However, other
growth factors such as fibroblast growth
factors (FGF), insulin-like growth factors
(IGF), members of the transforming
growth factor-β family (TGF-β), stem
cell factor (SCF) and several other growth
factors have in culture been shown to have
neuronal survival promoting effects
(Arumäe et al., 1997; Barde, 1989). Most
neurotrophic factors are synthesized as
precursor pre-pro proteins with a
consensus secretory signal sequence
which is cleaved in the endoplasmatic
reticulum (ER) (Lessmann et al., 2003).
Additional modifications occur in the
Golgi where the pro-domain is cleaved.
The neurotrophic factors are transported
in vesicles to the cell membrane where
they are released into the extracellular
space. Most of the biologically active
neurotrophic factors act as homodimers
either by binding to single- or
multicomponent receptors located on the
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3same cell (autocrine) or on neighbouring
cells (paracrine mode of action). The
signaling components are usually
transmembrane tyrosine or serine/
threonine kinase receptors that
autophosphorylate themselves upon
growth factor binding and thus initiate
intracellular signaling cascades leading to
immediate, early and late responses in the
cell.
The prototypic neurotrophic factor,
nerve growth factor (NGF), was
identified 50 years ago as a factor that
induced neuronal growth (Levi-
Montalcini, 1952). Brain-derived
neurotrophic factor (BDNF) isolated
from pig brain in the beginning of 1980´s
was shown to be highly homologous to
NGF. Shortly thereafter the family of
neurotrophins was expanded to include
two structurally and functionally similar
members, neurotrophin 3 (NT-3) and
neurotrophin 4/5 (NT-4/5) (reviewed by
Huang and Reichardt, 2001; Sofroniew et
al., 2001). The neurotrophins share a
common transmembrane low affinity
receptor (p75NTR) but use different
members of the Trk (tropomyosin-related
receptor kinase) family tyrosine kinase
receptors for high affinity binding and
signaling. NGF is the preferred ligand for
TrkA, BDNF and NT-4 for TrkB and NT-
3 for TrkC. The p75NTR receptor,
belonging to the family of tumor necrosis
factor receptors (TNFR), can induce
death in both neuronal and non-neuronal
cells in the presence of neurotrophin
when its high affinity receptor Trk is
absent (reviewed by Teng and Hempstead,
2004). Although proneurotrophins have
been considered as inactive precursors, at
least secreted proNGF has recently been
reported to induce apoptosis by binding
with high affinity to p75NTR and sortilin,
a 95 kDa receptor for neurotensin, in
sympathetic neurons and cells expressing
both receptors (Nykjaer et al., 2004).
Neuropoietic cytokines such as ciliary
neurotrophic factor (CNTF), interleukin-
6 (IL-6) and leukemia inhibitory factor
(LIF) are pleiotrophic cytokines which
are produced by immune cells, Schwann
cells, fibroblasts and sensory neurons.
Together with neurotrophins they act as
communicators between the immune and
nervous system and are known to act in
response to injury and stress (Otten et al.,
2000; Sariola et al., 1994; Sleeman et al.,
2000). All neurokines bind to a common
transmembrane glycoprotein receptor
gp130. In addition CNTF binds to a
glycosyl-phospatidylinositol (GPI)-
linked CNTFRα receptor and LIFRβ, LIF
to LIF-R and IL-6 to IL-6-R (Heinrich et
al., 2003). The ligand binding leads to
activation of Janus kinases (JAK) and
subsequent activation of STATs (signal
transducer and activator of transcription).
The GDNF family ligands (GFLs)
include four members: GDNF (Lin et al.,
1993), neurturin (NRTN, Kotzbauer et al.,
1996), persephin (PSPN, Milbrandt et al.,
1998) and artemin (ARTN, Baloh et al.,
1998b; Enovin, Masure et al., 1999;
Neublastin, Rosenblad et al., 2000). They
are small dimeric proteins secreted by the
target tissue which promote the survival
of central and peripheral neurons in vitro
and/or in vivo. GDNF protects dopamine
neurons in animal models of Parkinson´s
disease and rescues motor neurons in vivo
which makes it a valuable candidate for
therapeutic use in several
neurodegenerative diseases (reviewed by
Airaksinen and Saarma, 2002). Outside
the nervous system GDNF acts as a
morphogen in kidney development. Each
ligand binds to a preferred GDNF family
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4co-receptor (GFRα1-4) which is linked to
the outer leaflet of the cell membrane
with a GPI-anchor. Ligand binds to the
co-receptor and triggers the
transmembrane Ret tyrosine kinase
receptor, dimerizing and trans-
phosphorylating its intracellular tyrosine
residues. GDNF preferentially binds to
GFRα1, NRTN to GFRα2, ARTN to
GFRα3 and PSPN to GFRα4. Activating
mutations in the human RET receptor
cause different types of cancers in the
thyroid gland, whereas inactivating
mutations cause Hirschsprungs´s disease
which is characterized by the absence of
neuronal ganglia in various parts of the
colon (reviewed by Sariola and Saarma,
2003). The different actions and features
of GFLs and their receptors will be
discussed in detail below. Furthermore,
the results and discussion chapter will
deal with the characterization and roles of
the mammalian GFRα4 in more detail
(publications I, II and III).
1.2 Roles for neurotrophic factors
 outside the nervous system
The neurotrophins have been extensively
studied as molecules important for the
survival and differentiation of both
central and peripheral neurons (reviewed
by Fariñas, 1999; Huang and Reichardt,
2001). However, recent f indings have
pointed to a diversity of roles for the
neurotrophins outside the nervous
system. NGF (and to some extent NT-3
and BDNF) stimulate proliferation,
antibody synthesis and differentiation of
a broad spectrum of cell types in the
immune system (reviewed by Vega et al.,
2003). Gene ablation studies for Trk
receptors and their ligands have revealed
that TrkC and NT-3 are important for
cardiac outflow tract development
(Donovan et al., 1996; Srivastava and
Olson, 1996). Furthermore, both TrkA-
and TrkB-def icient mice showed
structurally abnormal thymus with lower
density of thymocytes and increased
apotosis leading to depletion of T- and B-
cells, suggesting that both NGF and
BDNF are important for the survival of
immune cells and in thymic
organogenesis (García-Suárez et al.,
2000; García-Suárez et al., 2002). Levels
of NGF are increased during
inflammation, allergies and diseases of
the immune system secondary to an initial
rise in anti-inflammatory cytokines
(reviewed by Levi-Montalcini et al.,
1996). In agreement with this, NGF can
suppress inflammation in the brain in an
animal model for human multiple
sclerosis (Villoslada and Genain, 2004).
Neurotrophins may thus function in the
maintenance of immune cells as well as
in repressing the inflammatory response.
BDNF-deficiency in mice has been
shown to result in cardiac vascular
hemorrhage leading to early postnatal
death (Donovan et al., 2000).
Furthermore, BDNF has been shown to
support the survival of cardiac endothelial
cells endogenously expressing TrkB and
increase capillary density if
overexpressed. NGF has been shown to
indirectly stimulate the release of vascular
endothelial growth factors from
endothelial cells and to stimulate wound
healing after experimental limb ischemia
(Emanueli et al., 2003). The complete
absence of p75NTR results in defects of
blood vessel formation (von Schack et al.,
2001), which further suggests an
angiogenic role for neurotrophins.
Expression of neurotrophins and their
receptors in germ cells and Sertoli cells
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5of the testis has suggested a role in germ
cell development (Ayer-LeLièvre et al.,
1988; Park et al., 2001). According to this,
increased germ cell apoptosis and
developmentally delayed gonad
morphology was detected from
embryonic and postnatal testicles of TrkA
and TrkC homozygous knockout mice
compared to wild-type mice (Cupp et al.,
2002). Neurotrophic factors are also
involved in hair follicle cycle as NGF/
TrkA and NT-3/TrkC signaling appear to
stimulate hair follicle development
(anagen), whereas NT-4, BDNF and
p75NTR are involved in the induction of
apototic hair follicle regression (catagen)
(Botchkarev et al., 2004).
Gene knockout studies of gp130, the
common signaling receptor for the IL-6
family of cytokines and IL-6 itself, have
revealed that gp130/IL-6 signaling is
important for protective response of
hepatocytes in liver injury (Streetz et al.,
2003; Wuestefeld et al., 2003). Specific
inactivation of gp130 in germ cells
resulted in a major defect in ovulation
whereas only a slight decrease in the
number of germ cells (Molyneaux et al.,
2003). The IL-6 family members are
potent inhibitors of stem cell
differentiation. LIF is commonly used in
maintaining the undifferentiated state of
embryonic stem cells in culture (Williams
et al., 1988). Furthermore, LIF has been
shown to be critical for blastocyst
implantation (Robb et al., 2002). In
addition, LIF has been found to induce
differentiation of kidney mesenchyme to
epithelia (Barasch et al., 1999) and is also
suggested to be involved in regeneration
of renal epithelium after acute injury
(Yoshino et al., 2003). LIF and CNTF
have in vitro shown to enhance the
survival of Sertoli cells and gonocytes,
which suggests that these factors may
play a role in the initial steps of
spermatogenesis (De Miguel et al., 1996).
GDNF family members may also
contribute to the control of the follicle
hair cycle. Gfra1, Gfra2 and their ligands
are highly expressed in the hair follicle
during the anagen (active growth)-
catagen (growth regression) transition
(Botchkareva et al., 2000).  Furthermore,
NRTN and GDNF administered to mouse
skin organ cultures retard hair follicle
regression. In line with the previous
results, Ret immunostaining has been
shown in mouse hair follicles after birth
(Kato et al., 2001). Interestingly,
promotion of hair growth occurred in a
transgenic mouse line overexpressing Ret
in the skin (Kato et al., 2001), suggesting
potential roles for GDNF/RET in human
hair growth promotion.
GDNF and its receptors GFRα1 and
Ret are crucial for ureteric branching in
kidney development as respective gene
knockout mice show relatively similar
phenotypes, all lacking kidneys (See
chapter 1.6.1). Furthermore, GDNF
expressed by Sertoli cells in the testis is
implicated in sperm differentiation and
will be discussed in the result and
discussion part of this thesis (publication
IV).
1.3 Glial cell line-derived neurotrophic
factor Family Ligands (GFLs) are
distant members of the TGF-β
family
1.3.1 GDNF
GDNF was biochemically purified in
1993 from a rat glioma cell line B49
growth medium on the basis of its ability
to promote the survival of embryonic
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6dopamine neurons in culture (Lin et al.,
1993; Lin et al., 1994). The full-length
GDNF cDNA  (633 bp) codes for a 211
amino acid precursor polypeptide with an
amino-terminal signal sequence and a
pro-sequence which is cleaved from the
mature domain by a furin-like
endoproteinase at a RXXR cleavage site
(Lin et al., 1993) (Fig. 1B; Table 1).
However, little is known about the
processing and secretion of GDNF by
neurons and non-neuronal cells in vivo.
The mature protein consists of 134 amino
acids (Mr 18-22kDa) and contains two
putative glycosylation sites (Lin et al.,
1993). GDNF contains seven cysteines in
the same relative spacing as members of
the TGF-β family (Chang et al., 2002;
Eigenbrot and Gerber, 1997) although
mature GDNF shares less than 20%
sequence homology on amino acid level
with any of the other TGF-β family
members (Lin et al., 1993). According to
the crystal structure the GDNF monomer
forms two f inger-like (Finger 1 and
Finger 2) structures by pairs of anti-
parallel β-strands with a α-helix at the
opposite end (Chen et al., 2000; Eigenbrot
and Gerber, 1997; Eketjäll et al., 1999)
(Fig. 1A). A compact cystine knot
structure, also common for other TGF-β
superfamily members is produced by six
cysteines forming three intermolecular
cystinyl bonds (Eigenbrot and Gerber,
1997; Ibáñez, 1998). The biologically
active GDNF dimer is formed by a
covalent disulf ide bond between the
unpaired cysteines in monomers, which
positions the monomers in a head-to-tail
orientation with the knot structure in the
middle of the dimer (Eigenbrot and
Gerber, 1997; Eketjäll et al., 1999).
GDNF mRNA is expressed in many
areas of the central and peripheral
nervous system during embryonic
development (Henderson et al., 1994;
Nosrat et al., 1996; Golden et al., 1999)
and after birth (Golden et al., 1998; Holm
et al., 2002; Nosrat et al., 1996; Trupp et
al., 1996). GDNF mRNA is also
expressed by developing skeletal muscles
(Arce et al., 1998; Chen et al., 2003;
Henderson et al., 1994; Nosrat et al.,
1996) and muscle layers of the gut wall
(Golden et al., 1999; Nosrat et al., 1996;
Suvanto et al., 1996). High levels of
GDNF mRNA is expressed in the
developing kidney mesenchyme
surrounding the tips of ureteric buds
(Nosrat et al., 1996; Sainio et al., 1997;
Suvanto et al., 1996), in developing
mouse whisker follicles and testis
(Suvanto et al., 1996; Trupp et al., 1995).
Expression of GDNF mRNA has also
been detected in the mesenchyme of
developing limb buds, tongue, teeth and
cartilage and in adult ovary (Golden et al.,
1999; Luukko et al., 1997; Nosrat et al.,
1996; Trupp et al., 1995), but the exact
role of GDNF in these organs is unclear.
GDNF supports in vitro the survival of
midbrain dopamine neurons (Lin et al.,
1993; Tomac et al., 1995), motoneurons
(Henderson et al., 1994; Oppenheim et
al., 1995), central noradrenergic neurons
(Arenas et al., 1995), basal forebrain
cholinergic neurons (Williams et al.,
1996), peripheral sensory,
parasympathetic, and sympathetic
neurons (Arce et al., 1998; Buj-Bello et
al., 1995; Forgie et al., 1999; Mount et al.,
1995; Oppenheim et al., 1995; Trupp et
al., 1995) and enteric neurons
(Heuckeroth et al., 1998).
In vivo exogenous GDNF has been
shown to prevent axotomized embryonic
or injured adult motoneurons from
atrophy and death and to induce sprouting
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2000; Li et al., 1995), which suggest that
GDNF could be a potential therapeutic
agent for the treatment of adult-onset
motoneuron diseases, such as
amyotrophic lateral sclerosis (ALS), a
progressively paralysing disease affecting
motoneurons. Animal models of
Parkinson´s disease (PD) have shown that
GDNF delivered to the striatum or
substantia nigra can prevent further cell
loss and also to restore function in
dysfunctional or atrophic neurons in the
degenerating nigrostriatal system
(Björklund et al., 2000; Åkerud et al.,
1999). In a recent clinical trial where
GDNF was delivered directly to the
putamen of f ive human PD patients,
improvement in motorfunction with no
side effects was reported (Gill et al.,
2003), suggesting further GDNF as a
potent candidate drug for treatment of PD.
In rodents, an increase in GDNF mRNA
and its receptors have been observed in
the forebrain, hippocampus and in the
striatum after experimentally induced
global and focal forebrain ischemia and
after kindling-stimulated epilepsy
(Arvidsson et al., 2001; Kokaia et al.,
1999). Direct delivery of GDNF before
ischemic insult has shown to block the
elevation of extracellular nitric oxide and
reduce the infarction size (Wang et al.,
1997). However, high doses of GDNF
may increase ischemic cell death due to
a yet unknown mechanism (Arvidsson et
al., 2003). In animal models of
experimentally induced neuropathic pain
arising from injury in peripheral nerves,
infusion of GDNF has been shown to
normalize abnormal pain behaviour and
restore the changes in neurochemical
markers observed in neuropathic pain
(reviewed by Sah et al., 2003). However,
the broad expression range of the
receptors for GDNF may elicit
complicated side effects by activating
cells normally silent.
1.3.2 Neurturin (NRTN)
NRTN was isolated from conditioned
medium of Chinese hamster ovary cells
on the basis of its ability to promote the
survival of neonatal rat sympathetic
neurons (Kotzbauer et al., 1996). Mature
NRTN shows 42% sequence similarity
with GDNF and has a predicted Mr of
12.5 kDa (Kotzbauer et al., 1996). Like
GDNF, NRTN is synthesized as a prepro
protein with seven cysteines in the same
relative spacing as GDNF (Fig. 1B; Table
1). Since seven cysteines are also
conserved in NRTN, it is likely that the
general fold of NRTN is very similar to
that of GDNF. However, data about the
three dimensional structure of NRTN is
lacking.
NRTN mRNA is detected in the
developing brain, in dental epithelium
and in developing lacrimal gland (Golden
et al., 1999; Luukko et al., 1998; Rossi et
al., 1999); Widenfalk et al., 1997). In
addition, high NRTN mRNA levels are
detected before birth in blood vessels,
skin, testis, circular muscle layer of the
gut, cutaneous glands, submandibular
gland, and parotid gland (Golden et al.,
1999; Widenfalk et al., 1997; Åkerud et
al., 1999). Postnatally, NRTN expression
remains high in skin, stomach, intestine,
prostate, testis and urethra (Golden et al.,
1999; Viglietto et al., 2000). In vitro
NRTN supports the survival of
populations of sensory and sympathetic
neurons (Forgie et al., 1999; Kotzbauer et
al., 1996), spinal motor neurons (Garcès
et al., 2001), dopaminergic neurons
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1996; Åkerud et al., 1999), enteric
neuronal precursor cells (Heuckeroth et
al., 1998) and basal forebrain cholinergic
neurons (Golden et al., 2003).
In vivo, exogenous NRTN has been
shown to prevent the death of dopamine
neurons in mouse models of Parkinson´s
disease (Horger et al., 1998; Åkerud et al.,
1999) but in contrast to GDNF, it does not
induce sprouting, neuritogenesis or
hypertrophy. However, the mechanism for
NRTN action is elusive, as GFRα2
expression has not been detected in
dopamine neurons.
1.3.3 Persephin (PSPN)
PSPN was identified in 1998 by PCR, and
subsequent rapid amplification of cDNA
ends (RACE), using degenerate primers
corresponding to very similar sequences
in GDNF and NRTN (Milbrandt et al.,
1998). Rat, mouse and human PSPN is a
156-amino acid long prepro protein with
a predicted 21-residue signal sequence, a
39-residue pro region, a RXXR consensus
cleavage site and a predicted 96-amino
acid mature PSPN protein of Mr 10-12
kDa.  PSPN shows about 40% sequence
identity to GDNF and 50% to NRTN, with
seven cysteines in the same characteristic
spacing as other members of the TGF-β
family (Milbrandt et al., 1998) (Fig. 1B;
Table 1).
The expression of PSPN mRNA is
very low in many rat embryonic and adult
peripheral tissues as well as in many parts
of the CNS and some sensory ganglia
(Jaszai et al., 1998; Milbrandt et al.,
1998). Because of its low expression,
PSPN mRNA has been detected only by
Figure 1. (A) Alpha-carbon chain feature of the GDNF homodimer. Adapted from (Eketjäll
et al., 1999). (B) Schematic organization of the prepro GFLs. According to (Airaksinen et
al., 1999). The relative lengths (number of amino acids) of pre-, pro- and mature domains of
GFLs are shown. Conserved cysteines in the mature domains are marked by black lines and
arrows.
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Curiously, the cDNA clones obtained
from mouse, rat and human cDNA
libraries contained an 88-bp intronic
sequence, which was in vitro removed by
splicing in mammalian cell lines
transfected with the cDNA containing the
short intron, to generate a transcript
coding for the prepro PSPN (Milbrandt et
al., 1998). In contrast, the intronic,
unspliced transcript generates a
premature stop codon when translated
which does not give rise to a functional
protein. As shown for GDNF and NRTN,
PSPN can promote the survival of
cultured rat embryonic midbrain
dopamine neurons and rat embryonic
motor neurons (Milbrandt et al., 1998;
Åkerud et al., 2002). PSPN also promotes
neurite outgrowth from chicken
embryonic oculomotor neurons in vitro
(Chen et al., 2003), but not postnatal rat
motor neurons (Bilak et al., 1999).
Recently, PSPN was also reported to
promote the survival of embryonic rat
basal forebrain cholinergic neurons
(Golden et al., 2003). However, in
contrast to GDNF and NRTN, PSPN does
not promote the survival of cultured rat
peripheral sympathetic, sensory or enteric
neurons (Milbrandt et al., 1998). In vivo,
PSPN signaling may protect the brain
from insults as PSPN administered
intraventricularly prior to experimentally
induced focal cerebral ischemia, is shown
to reduce the infarction size in mice and
rats (Tomac et al., 2002). Furthermore,
PSPN expressed by a neural stem cell line
grafted to the striatal area in mouse was
shown to rescue dopamine neurons from
degeneration in a mouse model of
Parkinson´s disease (Åkerud et al., 2002).
1.3.4 Artemin (ARTN)
ARTN (also named Enovin or Neublastin)
the fourth member of the GDNF family,
was independently identified by three
groups using database homology search
(Baloh et al., 1998b; Masure et al., 1999;
Rosenblad et al., 2000). Full-length ARTN
cDNA was obtained by RACE PCR from
mouse and human cDNA libraries.
Sequence data revealed that ARTN is a
member of the GDNF family ligands (Fig.
1B; Table 1). Mature ARTN has the
highest sequence identity to NRTN (51%)
and PSPN (53%) and the lowest to GDNF
(39%) (Masure et al., 1999). In rat and
mouse embryos, ARTN mRNA expression
is localized in close proximity to
migration routes for sympathetic
neuroblasts, in the wall of the dorsal aorta
near the site of the organization of the
primitive sympathetic chain and later its
expression is localized to blood vessels
and arteries along which sympathetic
neurons migrate and differentiate
(Enomoto et al., 2001; Honma et al.,
2002). Artn mRNA has not been detected
in the CNS. In vitro, ARTN is found to
support the survival of a subset of sensory
and sympathetic neurons (Baloh et al.,
1998b; Enomoto et al., 2001). Recent
studies have shown that ARTN can
reverse experimental neuropathic pain,
which suggests ARTN application as a
treatment for different types of
neuropathic pain (Gardell et al., 2003).
1.4 GDNF family receptor α´s
(GFRα´s)
GFRα1, the preferential binding receptor
for GDNF, initially termed GDNFR-α,
was cloned by expression cDNA library
screening and characterized
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independently by two groups (Jing et al.,
1996; Treanor et al., 1996) (Table 1). This
proved to be a novel class of cysteine rich
proteins (31 Cys of 468 amino acids) with
three N-glycosylation sites and a
predicted Mr of 47 kDa. GFRα1 contains
a N-terminal hydrophobic area
characteristic for a secretory signal
sequence (von Heijne, 1986) and a C-
terminal sequence with 23 hydrophobic
amino acids. A group of three small
amino acids (ASS) proceeding the stretch
of hydrophobic amino acids indicated a
Gene Human  
Localization
Accession1, bp2
Mouse
Localization
Accession, bp
Rat
Localization
Accession, bp 
Chicken 
Localization
Accession, bp 
GDNF 5p13.1
NM_000514  
633 bp 
15A2
NM_010275  
720 bp 
2q16
NM_019139  
717 bp 
Unknown*
AF176017
Partial cDNA 
NRTN 19p13.3
NM_004558  
591 bp 
17D
NM_008738  
585 bp 
9q11
NM_053399  
671 bp 
28*
PSPN 19p13.3
NM_004158  
468 bp 
17E1.1
NM_008954  
468 bp 
9q11
NM_013014  
468 bp 
Unidentified* 
ARTN 1p34.1
NM_003976 
660 bp 
14D1
NM_009711  
672 bp 
5q36
AF_184919
675 bp 
8*
GFRA1 10q25.3
NM_005264  
1395 bp 
19D3
NM_010279  
1404 bp 
1q55
NM_012959  
1407 bp 
6*
NM_205102  
1407 bp 
GFRA2 8p21.3
NM_001495  
1392 bp 
14D1
NM_008115  
1389 bp 
15p11
NM_012750  
1392 bp 
Unknown*
NM_205101, 
GFRA3 5q31.2
NM_001496  
1200 bp 
18
NM_010280  
1191 bp 
18p12
XM_341593  
1267 bp 
13*
GFRA4 20p13
AJ291673, 807 bp (a) 
AJ291674, 897 bp (b) 
2F3
AJ276870, 780 bp (GPI) 
AJ276871, 879 bp (TM) 
3q36
NM_023967 
822 bp
4*
NM_204991 
1293 bp 
RET 10q11.21
NM_000323 long  
3342 bp 
NM_020630 short 
3216 bp 
6F1
NM_009050 long 
3345 bp 
AY_326937 short 
3219 bp 
4q42
AJ_299016 long 
3348 bp 
AJ_299017 short 
3222 bp 
6?* 
NM_205190 
3192 bp short 
possible GPI-binding/cleavage site
(Udenfriend and Kodukula, 1995). The
GPI-linkage was verified by treatment of
GFRα1 expressing cells with
p h o s p h a t i d y l i n o s i t o l - s p e c i f i c
phospholipase C (PI-PLC) which cleaves
GPI-linked proteins from the cell surface
(Jing et al., 1996; Treanor et al., 1996).
The GFRα1 receptor was found to bind
125I-GDNF with high affinity, and this
binding was effectively displaced with an
excess of unlabeled GDNF (Cik et al.,
2000). Immunoprecipitation of Ret
Table 1. Chromosomal localization of GFL, GFRA and RET genes.
 1 Genbank Accession number, 2 coding region, * localization based on BLAST analysis of the
draft chicken genome assembly (http://www.genome.gov/11510730).
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protein tyrosine kinase after cross-linking
of 125I-labeled GDNF to GFRα1 revealed
that GDNF-GFRα1 forms a complex
with the Ret receptor. The pattern of
bands in reducing and non-reducing gels
suggested that a GDNF dimer binds to a
GFRα1 dimer that forms a complex with
RET. GDNF was also shown to activate
Ret tyrosine kinase when bound to either
soluble or GPI-linked GFRα1 receptor
(Jing et al., 1997).
Gfra1 mRNA is expressed in many
brain areas of the developing and adult
mouse which often is complementary to
the sites where GDNF is expressed
(Golden et al., 1998; Golden et al., 1999;
Nosrat et al., 1997; Trupp et al., 1997).
High Gfra1 mRNA levels are detected in
some peripheral organs of the developing
mouse and rat such as the ureteric buds
and mesenchyme of the kidney, the
ganglionic plexuses of the developing
gastrointestinal tract and whisker follicles
(Golden et al., 1999; Nosrat et al., 1997;
Yu et al., 1998).
Homology database searching using
GFRα1 as a query resulted in the
simultaneous cloning of GFRα2 (TrnR2,
Baloh et al., 1997; NTNR-α, Buj-Bello et
al., 1997; GFRα-2, Jing et al., 1997;
NTNR-α, Klein et al., 1997; RETL2,
Sanicola et al., 1997; GDNFR-β, Suvanto
et al., 1997; GDNFR-β, Wang et al., 1998;
GDNFR-β, Widenfalk et al., 1997) (Table
1). GFRα2 contains 464 amino acids with
a predicted molecular weight of
approximately 51 kDa and shares a
significant homology with GFRα1 (48%)
as well as nearly identical spacing of 30
of its 31 cysteines. GFRα2 contains a
signal peptide at the amino terminus,
three potential glycosylation sites and a
GPI cleavage/binding site (Udenfriend
and Kodukula, 1995). On the basis of
internal homologous cysteine-rich
sequences in GFRα1 and GFRα2, a
secondary structure analysis prediction
suggested three putative globular
cysteine-rich domain structures in the two
receptors (D1-D3), linked with less
conserved hinge domains (Airaksinen et
al., 1999; Suvanto, 1997) (Fig. 2). This
domain model was recently verified by
crystallization of GFRα1 D3 which
revealed a new protein fold (Leppänen et
al., 2004). The D3 domain forms a bundle
of five α-helices connected with three
less well-conserved loops. Five disulfide
bridges form a compact structure
including five conserved hydrophobic
phenylalanines which form the core of the
bundle. D1 and D2 were predicted to have
the same structure as D3 on the basis of
α-helical structure and conserved
cysteines with the same positions with
respect to disulfide bridges (Leppänen et
al., 2004). Binding data revealed that
NRTN binds with high affinity (K
d
 10
pM) to the GFRα2 receptor (Cik et al.,
2000; Klein et al., 1997). NRTN like
GDNF was found to stimulate Ret
phosphorylation in cell lines co-
expressing Ret and GFRα2 (Baloh et al.,
1997; Jing et al., 1997; Klein et al., 1997;
Suvanto et al., 1997).
Gfra2 mRNA is expressed in the
embryonic as well as adult CNS and PNS
neurons and glia such as parasympathetic
and enteric neurons and glia, in some
sensory neurons, in the developing and
postnatal myenteric plexus of the
gastrointestinal tract and many peripheral
organs (Golden et al., 1998; Golden et al.,
1999; Heuckeroth et al., 1999; Jing et al.,
1997; Rossi et al., 1999; Rossi et al.,
2003; Suvanto et al., 1997; Widenfalk et
al., 1997).
GFRα3, the third member of the
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GFRα family was cloned by PCR (Baloh
et al., 1998a; Jing et al., 1997; Masure et
al., 1998; Naveilhan et al., 1998; Nomoto
et al., 1998; Trupp et al., 1998; Widenfalk
et al., 1998; Worby et al., 1998) (Table 1).
GFRα3 (Mr 39 kDa) is 34% identical to
GFRα1 and 36% identical to GFRα2
(Fig. 2). The conserved 28 cysteines
suggested a similar domain structure as
for GFRα1 and GFRα2 but with a shorter,
less conserved C-terminal. Gfra3 mRNA
is expressed in some embryonic and adult
sensory ganglia and throughout the entire
sympathetic nervous system but not in the
brain (Baloh et al., 1998a; Honma et al.,
2002; Trupp et al., 1998; Widenfalk et al.,
1998; Worby et al., 1998).
Chicken GFRα4 was identified from
an embryonic chicken brain cDNA library
by low stringency hybridization to a
GFRα1 probe. The amino acid sequence
revealed a 431-amino acid long protein
with 28 conserved cysteines, a N-terminal
putative hydrophobic signal sequence,
and a putative consensus GPI-linkage
sequence in the C-terminus, characteristic
for the other GFRα receptors (Thompson
et al., 1998). Sequence alignment
revealed that chicken GFRα4 shares
higher identity with both mouse and
chicken GFRα1 and GFRα2 (40%) than
with mouse GFRα3 (27%). In
displacement binding experiments with
different ligands, only mouse PSPN, but
not rat GDNF nor human NRTN, was
capable of binding to chicken GFRα4
(Enokido et al., 1998). However, higher
concentrations (K
d
 approximately 1 nM)
of unlabelled PSPN were needed for
displacement compared to GDNF binding
to GFRα1 and NRTN to GFRα2
(Enokido et al., 1998). Furthermore, Ret
was shown to be the signaling receptor for
PSPN together with GFRα4 as
sympathetic neurons co-expressing
GFRα4 and Ret, but not GFRα1 or
GFRα2, survived in the presence of PSPN
(Enokido et al., 1998). Chicken Gfra4
mRNA was found to be expressed in
embryonic kidney, skeletal muscle, skin,
intestine and lung and within the CNS in
spinal cord, cerebellum, midbrain,
medulla oblongata and pons (Thompson
et al., 1998). The mammalian GFRα4 was
characterized in this work and its features
compared to the other GFRα-receptors
will be described in detail in the results
and discussion part (I and II) (Fig. 2)
(Table 1).
1.5 RET receptor tyrosine kinase
RET was identified in 1985 as an
oncogene resulting from a chromosomal
translocation during transfection of
human lymphoma DNA into a fibroblast
cell line (REarranged during
Transfection) (Iwamoto et al., 1993;
Takahashi et al., 1985; Takahashi, 1988)
(Table 1). The RET proto-oncogene
encodes for a single span transmembane
protein with an extracellular domain (607
amino acids) consisting of four cadherin-
like repeats (CDL1-4) based on computer
modeling (Anders et al., 2001), a cysteine
rich domain (Iwamoto et al., 1993; Kuma
et al., 1993; Takahashi, 1988; Takahashi
et al., 1989), a hydrophobic
transmembrane region, and a cytoplasmic
intracellular part (414 or 457 aa) with a
kinase domain (amino acids 724-1016)
divided in human RET into two lobes by
a hinge region (Scott, 2002) (Fig. 2). A
Ca2+-binding site is localized between
cadherin-like domains 2 and 3 (Anders et
al., 2001). Two RET polypeptides with
different molecular masses are usually
seen in western blots, one fully processed,
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membrane-bound protein of
approximately 170 kDa and one smaller,
partially glycosylated protein of
approximately 150 kDa band that is
thought to retain in the endoplasmatic
reticulum (Carlomagno et al., 1996;
Cosma et al., 1998). The RET gene
encodes for multiple alternative 5´and
3´end splice variants (Ivanchuk et al.,
1997; Lorenzo et al., 1995; Myers et al.,
1995; Tahira et al., 1990). Alternative
splicing of the 3´ RET mRNA gives rise
to at least three RET isoforms differing
in their C terminus downstream of amino
acid 1062. The short isoform (1072 aa)
with a 9-amino acid unique C-terminus
and the long isoform (1114 aa) with 51-
amino acid unique C terminus, are highly
conserved between species (Carter et al.,
2001). The short isoform (RET9) is
important for early kidney and enteric
nervous system development (de Graaff
et al., 2001; Lee et al., 2002), whereas the
long isoform (RET51) is important for the
metabolism and growth of mature
sympathetic neurons (Tsui-Pierchala et
al., 2002a). RET transcripts are expressed
in cells and tissues derived from the
neural crest, branchial arches and ureteric
bud (Lorenzo et al., 1995) often
overlapping with the expression of GFRα
receptor mRNAs (Trupp et al., 1997).
Expression of RET is high in dopamine
neurons, in motor neurons, in a subset of
trigeminal neurons, gastrointestinal tract
and kidney (Nosrat et al., 1997). However,
the expression of RET is low or absent in
many developing and adult brain areas
such as hippocampus and developing
cerebellum (Golden et al., 1998; Golden
et al., 1999; Trupp et al., 1997).
Expression of RET mRNA is also
detected in the developing and adult
thyroid parafollicular C-cells (Belluardo
et al., 1999; Golden et al., 1999). High
levels of RET mRNAs have been
observed in human tumors with a neural
crest origin, such as medullary thyroid
Figure 2. Interaction of GFLs with their cognate receptors. All GFLs activate the
transmembrane tyrosine kinase RET through their preferred GFRá receptor (solid arrows).
Weak cross-talk has been observed with NRTN and ARTN binding to GFRá1 and GDNF
binding to GFRá2 (dotted arrows). The mammalian GFRá4 lacks the first Cys-rich domain
D1 (I, II). Adapted from (Airaksinen and Saarma, 2002).
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carcinoma and pheochromocytomas
derived from the adrenal medullary
chromaffin cells (Takaya et al., 1996).
Several gain-of-function mutations in the
RET gene result in human diseases
including familial medullary thyroid
carcinomas (FMTC), multiple endocrine
neoplasia types 2A and 2B (MEN2A and
MEN2B) and sporadic medullary and
papillary thyroid carcinoma characterized
by neoplasias of the thyroid gland (See
chapter 1.9.2). Loss-of-function
mutations in RET cause Hirschsprung´s
disease (HSCR) characterized by
megacolonic aganglionosis (See chapter
1.9.1).
1.6 Gene ablation studies reveal
distinct activities for GFLs in vivo
1.6.1 GDNF, GFRα1 and RET are
regulators in kidney morpho-
genesis and in the development of
the enteric and parasympathetic
nervous system
Many of the in vivo roles for GFLs,
GFRα- and RET receptors and their
interactions inside and outside the
nervous system have been elucidated by
gene ablation studies. Homozygous Ret-
deficient mice (Schuchardt et al., 1994)
as well as GDNF- (Moore et al., 1996;
Pichel et al., 1996; Sánchez et al., 1996)
and GFRα1-deficient mice (Cacalano et
al., 1998; Enomoto et al., 1998) all display
unilateral or bilateral renal agenesis or
severe dysgenesis and lack of enteric
neurons from the myenteric plexus in the
small and large intestine (intestinal
aganglionosis) (Table 2). However, the
rest of the urogenital system such as
gonads and the adrenal glands develop
normally (Allmendinger et al., 2003).
Consequently, these mice die 12-24 hours
after birth possibly due to an inability to
consume milk, a renal failure or/and a
breathing defect.
Kidney development is characterized
by a successive interaction of inductive
signals between the metanephric blastema
and the ureteric bud which branches from
the Wolff ian (nephric) duct into the
metanephric blastema. The mesenchyme
signals the proliferating bud both to
divide and to elongate its collecting ducts
(Suvanto, 1997). Gdnf mRNA is highly
expressed in the condensing metanephric
mesenchyme (Hellmich et al., 1996;
Suvanto et al., 1996), whereas Ret and
Gfra1 mRNA are expressed by the tips of
the ureteric bud (Sainio et al., 1997).
Gfra1 mRNA is also found in the
nephrogenic mesenchyme (Sainio et al.,
1997). GDNF has been shown to bind
directly to tips of the ureteric buds and
induce bud formation from the Wolffian
duct from local sources in organ cultures
(Sainio et al., 1997). In homozygous
GDNF-, GFRα1- and RET-deficient
mice, the ureteric bud is not developed
and if it is, it never reaches the
metanephric mesenchyme (Cacalano et
al., 1998; Enomoto et al., 1998; Moore et
al., 1996; Pichel et al., 1996; Sánchez et
al., 1996; Schuchardt et al., 1994;
Schuchardt et al., 1996), which suggests
GDNF and its receptors to be critical for
inducing the development of the ureteric
bud. GDNF heterozygous mice display
unilateral agenesis or bilateral
dysgenesis, indicating that the level of
GDNF produced by the nephrogenic
mesenchyme is critical in the inductive
process. Misexpression of RET mRNA
throughout the bud also causes variable
inhibition of ureteric bud growth and
branching, probably due to reduction of
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GDNF availability to the tips of the
ureteric bud (Srinivas et al., 1999).
However, signals other than GDNF are
likely to count for the growth and
elongation of the branches (Sariola and
Saarma, 1999). Although both NRTN and
PSPN in vitro can promote ureteric
branching (Davies et al., 1999; Milbrandt
et al., 1998), NRTN-, GFRα2- and PSPN-
deficient mice show no obvious defect in
kidney development (Heuckeroth et al.,
1999; Rossi et al., 1999; Tomac et al.,
2002).
The mammalian enteric nervous
system (ENS) controls digestive activities
such as peristaltic movements, endocrine
and exocrine secretions. The development
of the ENS starts with the migration of
vagal and trunk (somites 1-7) neural crest
cells (NC) from the neural tube
ventrolaterally to invade the foregut
mesenchyme. Previously, in vitro studies
have shown that GDNF and NRTN
promote the survival and proliferation of
mammalian ENS progenitor cells and
their differentiation into neurons and glia
(Heuckeroth et al., 1998; Taraviras and
Pachnis, 1999). GDNF has been shown to
be important for guiding NC cells to their
proper targets in the ENS and is expressed
in the mesenchyme ahead of the invading
NC cells that successively invade almost
the entire length of the bowel in the
developing mouse (Young et al., 2001;
Natarajan et al., 2002). Homozygous
GDNF-, GFRα1-and Ret-deficient mice
all lack neural crest derived enteric
neurons posterior to the stomach
(Cacalano et al., 1998; Enomoto et al.,
1998; Moore et al., 1996; Pichel et al.,
1996; Sánchez et al., 1996; Schuchardt et
al., 1994), a condition that resembles
Hirschsprung´s disease (HSCR), or
colonic aganglionosis in humans (Parisi
and Kapur, 2000). In a recent study,
knock-in mice were generated expressing
monoisoformic forms of either RET9 or
RET51 (de Graaff et al., 2001). The
majority of mice homozygous for RET9
died as neonates with a slightly milder
kidney- and ENS phenotype than Ret-
deficient mice. The RET9 homozygous
mice are characterized by distal colon
aganglionosis which is analogous to the
condition observed in HSCR (de Graaff
et al., 2001). In contrast to RET9 mice,
the RET51 homozygous mice are normal,
suggesting that RET9 is sufficient for
normal development of the kidneys and
the ENS (de Graaff et al., 2001).
Peripheral neuronal deficits were also
observed in GDNF-, GFRα1- and RET-
deficient mice. Certain cranial (otic and
sphenopalatine) parasympathetic ganglia
are missing in newborn GDNF-, GFRα1-
and Ret-mutant mice, indicating that
GDNF signaling is important for early
development of parasympathetic ganglia
(Enomoto et al., 2000; Marcos and
Pachnis, 1996; Rossi et al., 2000).
Furthermore, there is a significant loss of
a subset of motoneurons in homozygous
GDNF- and GFRα1-deficient embryos
(Cacalano et al., 1998; Moore et al., 1996;
Oppenheim et al., 2000; Sánchez et al.,
1996). Accordingly, the death of
motoneurons is prevented by over-
expression of GDNF in developing
muscle or by exogenously injecting
GDNF in utero (Oppenheim et al., 2000).
Furthermore, transgenic mice over-
expressing GDNF under a muscle-
specific promoter show hyperinnervation
of neuromuscular junctions (Nguyen et
al., 1998), suggesting GDNF to be
important for motor axon branching and
synapse elimination. Even though Gfra1
and to a lesser extent GDNF and Ret, are
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highly expressed in the central nervous
system of wild type mice, no obvious
defects were found in the CNS of these
mice at birth (Cacalano et al., 1998;
Enomoto et al., 1998; Moore et al., 1996;
Pichel et al., 1996; Sánchez et al., 1996).
Although GDNF is known to be a potent
survival factor for embryonic and mature
midbrain dopamine neurons, no loss of
dopamine neurons or projections to the
striatum was observed in GDNF-,
GFRα1- or Ret-deficient mice (Cacalano
et al., 1998; Enomoto et al., 1998; Marcos
and Pachnis, 1996; Moore et al., 1996;
Sánchez et al., 1996). However, these
mice die before maturation of the
dopaminergic system. In rodents DA
neurons undergo natural cell death in two
phases the first peaking just after birth
and the second 2 weeks after birth (Oo
and Burke, 1997). It has recently been
demonstrated that GDNF administred in
vivo into the striatal target is able to
suppress the natural apotosis during the
f irst biphasic death event (Oo et al.,
2003). In the same paradigm blocking
antibodies to endogenous GDNF induced
apotosis (Oo et al., 2003). Midbrain
dopamine neuronal grafts transplanted
from GDNF-null mouse fetuses, show
poor survival compared to wild type or
heterozygous tissue, when transplanted to
wild-type adult mouse brain (Granholm
et al., 2000), suggesting that GDNF is
important for the survival of adult
dopamine neurons. Moreover, GDNF is
suggested to have many functions in the
adult brain like in learning behavior, age
related motor dysfunctions and in
adaptation to drug abuse (Gerlai et al.,
2001; Grondin et al., 2003; Messer et al.,
2000). The best solution to in vivo study
the effect of GDNF-, GFRα1- and Ret-
deficiency in the young and adult mouse
would be to generate conditional knock-
out mice with def iciency in targeted
tissues.
1.6.2 NRTN and GFRα2 regulate the
development of parasympathetic
and subsets of enteric neurons
Homozygous GFRα2- and NRTN-
deficient mice are both viable and fertile,
show no obvious defects in major organs
and brain, but have a similar defect in the
cholinergic innervation of some
parasympathetic cranial ganglia and
enteric myenteric plexus (Heuckeroth et
al., 1999; Rossi et al., 1999) (Table 2).
Both mice show a reduction in tear
production caused by deficits in the
cholinergic innervation of the lacrimal
gland. Otic and sphenopalatine ganglia
are present in GFRα2- and NRTN-
deficient mice but reduced in neuronal
size (Heuckeroth et al., 1999; Rossi et al.,
1999). The sacral parasympathetic system
is also affected as GFRα2-deficient mice
have fewer parasympathetic axons
innervating the penis (Laurikainen et al.,
2000). It was shown recently that the
innervation of the mucosa of reproductive
organs by a subset of parasympathetic
cholinergic neurons was reduced in
GFRα2- and NRTN-deficient mice,
whereas the smooth muscle layers and the
urinary bladder were not affected
(Wanigasekara et al., 2004). The
reduction in parasympathetic neuronal
number and size in many of the cranial
and sacral parasympathetic ganglia
indicates NRTN/GFRα2/Ret signaling to
be important for parasympathetic target
innervation and maintenance of cell size
(Heuckeroth et al., 1999; Rossi et al.,
1999; Rossi et al., 2000; Wanigasekara et
al., 2004). Furthermore, a temporal
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Table 2. Phenotypes of mice lacking GFLs and their receptors. Modified from (Airaksinen
and Saarma, 2002).
NS, not significantly different from wild-type; ND, not determined; PG, petrosal ganglion;
DRG, dorsal root ganglion; TG, trigeminal ganglion; SCG, superior cervical ganglion; SPG,
sphenopalatine ganglion; OG, otic ganglion; SMG, submandibular ganglion; *Gdnf+/-, **
Gfra2-/- mice.
Gene Knock-
out
RET GDNF/GFR?1 NRTN/GFR?2 ARTN/GFR?3 PSPN/GFR?4
Gross
phenotype
P0 lethal P0 lethal Viable, fertile. 
Pseudoptosis 
growth 
retardation**
Viable, fertile 
Ptosis
Viable, fertile 
Gfra4-/-(III)
Breathing 
defect
<40%,
breathing  
defect
soma reduced 
Soma size 
reduced, loss of 
heat sensitivity 
NS
PNS:
Sensory:  
PG
DRG
TG
 loss in whisker 
follicles 
SCG;
migration 
defect
SCG;  <35% in 
Gdnf-/- mice 
NS in Gfra1-/-
mice 
NS SCG and other 
ganglia; defect 
in migration 
and axon 
growth 
Autonomic:
Sympathetic 
Sympathetic 
cholinergic
  Soma 
size,target
innervation 
reduced
Lack of 
ganglia 
Lack of ganglia NS
Lack  of 
ganglia 
Lack of ganglia 40% reduced 
no. of  neurons 
Parasympathetic 
Cranial:  
SPG
OG
SMG Reduced
number 
and soma 
size
Reduced
number and 
soma size 
42% reduced 
number  of 
neurons
NS
Enteric
neurons
No
neurons in 
bowel 
below 
stomach 
No neurons in 
bowel below 
stomach 
Moderate loss 
of fibers in 
small intestine 
NS
ND
Loss in 
various 
nuclei 
22-31% loss of 
neurons
No gross 
defects
No gross 
defects
No gross 
defects
CNS:
Spinal
motorneurons 
Brain Substantia 
nigra; ns 
impaired 
learning, 
reduced loco- 
motor activity* 
impaired 
behavioral 
flexibility and 
memory **
No gross 
defects
Pspn-/-:
hypersensitive 
to cerebral 
ischemia 
Other tissues No
kidneys, 
moderate 
thyroid C- 
cell loss(I) 
No kidneys, 
testis
degeneration in 
adult Gdnf+/-
mice (IV) 
ND ND Gfra4-/- mice; 
calcitonin 
levels reduced 
in young mice 
(III)
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switch from GDNF- to NRTN
dependence is suggested to occur in
parasympathetic and enteric neurons late
in embryonic development (Airaksinen
and Saarma, 2002). A subpopulation of
exicatory enteric neurons is lost in the
small intestine of GFRα2- and NRTN-
deficient mice and the motility of the gut
shows impairment in vitro (Heuckeroth et
al., 1999; Rossi et al., 1999). Interestingly,
NRTN/GFRα2/Ret signaling has also
proven to be important for adult
cholinergic sympathetic neurons as three-
week-old and adult GFRα2-deficient
mice have a reduced number of
cholinergic sympathetic neurons and
soma size in footpad sweat glands in
comparison to wild-types (Hiltunen and
Airaksinen, 2004).
GFRα2-deficient mice experience
growth retardation after birth compared
to wild-type littermates, which is most
pronounced at 4-6 weeks (Rossi et al.,
1999; Rossi et al., 2003), while this
phenotype is not observed in the NRTN-
deficient mice (Heuckeroth et al., 1999).
The differences between GFRα2-and
NRTN-deficient mice in growth, even
though fed with the same diet and bred
almost in the same background, suggest
that GFRα2/Ret signals yet through
another ligand in vivo (Wanigasekara et
al., 2004).
Although the morphology of the CNS
in GFRα2-deficient mice appears
normal, the GFRα2-def icient mice
display a suppressed response to epileptic
stimulus in a hippocampal kindling model
(Nanobashvili et al., 2000), which further
suggests functional roles for GFRα2 and
NRTN in the brain.
1.6.3 ARTN and GFRα3 control
sympathetic neuronal migration
and initial axon growth
As substantial sympathetic defects were
found in the homozygous RET knock-out
mice (Durbec et al., 1996; Enomoto et al.,
2001), it was logical to assume that
GFRα3 and ARTN are important
signaling mediators in the development of
sympathetic ganglia. Profound deficits in
the superior cervical ganglion (SCG) and
other sympathetic ganglia are found in
homozygous ARTN- and GFRα3-
deficient mice (Andres et al., 2001;
Honma et al., 2002; Nishino et al., 1999)
(Table 2). These mice are viable and
fertile and show no obvious defects in
major organs, but 30% of the mice suffer
from unilateral or bilateral ptosis caused
by loss of sympathetic innervation from
the SCG of the superior tarsus muscle
(Nishino et al., 1999). The SCG on the
ipsilateral side of the eye affected by
ptosis is lacking or smaller in size and
more caudally located. Newborn GFRα3-
and ARTN-deficient mice exhibit smaller
and aberrantly segmented sympathetic
chain ganglia with a deficiency in axonal
growth. It is well established that
sympathetic axons follow blood vessels to
reach their targets and it is now clear that
ARTN expressed by smooth muscle cells
in the wall of blood vessels probably acts
as a chemoattractant for the developing
sympathetic axons (Honma et al., 2002).
It is thus suggested that ARTN is critical
for guiding the migrating embryonic
sympathetic neuroblasts to their targets
and for guiding the axons to their
innervating target organs, whereas other
neurotrophic factors including NGF and
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NT-3, are important for their postnatal
survival and target innervation
(Airaksinen and Saarma, 2002; Honma et
al., 2002a). Compensatory mechanisms
in the sympathetic nervous system must
exist as most tissues eventually become
at least to some part innervated by
sympathetic neurons in the ARTN- and
GFRα3-deficient mice.
1.6.4 PSPN is suggested to protect the
brain from ischemic insult
PSPN-def icient mice are viable and
fertile and exhibit no gross abnormalities
in peripheral tissues or in the central
nervous system (Tomac et al., 2002)
(Table 2). Furthermore, extensive
behavioral tests showed no significant
abnormalities between PSPN-knockout
mice and wild-type littermates. However,
homozygous PSPN-deficient mice
demonstrated an increased sensitivity to
experimentally induced focal cerebral
ischemia (Tomac et al., 2002).
Furthermore, pretreatment of PSPN-
deficient mice with low dose of PSPN
(0.1 µg and 0.5 µg) before middle cerebral
artery occlusion (MCAO) was shown to
markedly reduce the infarction size and
enhanced vertical locomotor activity
compared to vechile-treated animals.
Interestingly, a high dose of PSPN (10 µg)
seemed toxic, as it increased the
infarction volume. In vitro, low doses of
PSPN were also able to inhibit cell death
of cortical neurons after hypoxia and
reoxygenation (Tomac et al., 2002). These
results suggest PSPN signaling through
mammalian GFRα4/Ret or yet another
receptor. The in vivo effects of the mouse
Gfra4 gene ablation will be discussed in
the results and discussion part of this
thesis (III).
1.7 RET-dependent signaling
1.7.1 Assembly of the GFL/GFRα/Ret
complex
GFLs are known to bind to a preferred
GFRα co-receptor and activate the
transmembrane receptor Ret (Baloh et al.,
1997; Baloh et al., 1998b, Enokido et al.,
1998; Jing et al., 1996; Klein et al., 1997;
Treanor et al., 1996; Trupp et al., 1996).
However, some cross-talk, at least in vitro,
can occur between receptors and ligands
(Fig. 2). NRTN and ARTN show weak
interaction with GFRα1, and GDNF with
GFRα2 (Baloh et al., 1997; Baloh et al.,
1998a, Baloh et al., 2000; Klein et al.,
1997; Sanicola et al., 1997; Suvanto et al.,
1997; Wang et al., 1998). The
physiological role for the cross-talk is
however not understood. Since Ret cannot
bind GDNF on its own, a model was first
proposed that GDNF dimer binds GFRα1
monomer/dimer recruiting thereafter two
Ret monomers into the complex leading
to c-Ret dimerization and activation of the
tyrosine kinase (Jing et al., 1996).
However, it has been also suggested that
GFRα-receptors and Ret are arranged in
a preformed complex and that ligand
binding stabilizes the complex (Eketjäll
et al., 1999; Klein et al., 1997; Scott and
Ibáñez, 2001; Treanor et al., 1996). The
latter part of this hypothesis is supported
by competition binding experiments,
showing higher affinity of GDNF to
GFRα1 in the presence of Ret (Cik et al.,
2000; Leppänen et al., 2004). Clearly,
further studies are needed to understand
the molecular events of GDNF/GFRα1/
Ret interaction.
Mutagenesis studies revealed 9 amino
acid residues (of which 5 are conserved
between other GFLs) on finger 1 and 2 of
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GDNF that are critical for binding to
GFRα1 (Eketjäll et al., 1999) (Fig. 1A).
Studies with truncated or chimeric
GFRα-receptors furthermore showed that
the N-terminal cysteine-rich domain (D1)
is dispensable for ligand binding to
GFRα-receptors and Ret phosphorylation
(Scott and Ibáñez, 2001). However,
binding of GDNF is reduced in GFRα1
lacking D1, which could be caused by a
loss of one of the two heparan sulphate
binding consensus sequences or by loss
of interaction with other receptors
(Barnett et al., 2002; Scott and Ibáñez,
2001). Heparan sulphates which are borne
by proteoglycans on the cell surface have
been shown to be important for GDNF
binding to GFRα1 in cell lines and
suggested to concentrate the ligand in the
vicinity of the receptor or to stabilize the
ligand-receptor complex (Barnett et al.,
2002; Rickard et al., 2003).  Distinct
ligand binding epitopes in domains 2 and
3 of GFR1α have been demonstrated to
be important for ligand binding and Ret
activation (Scott and Ibáñez, 2001).
Furthermore, the highly conserved amino
acid triplets 211MLF and 224RRR in D2
domain of GFRα1 show complementary
properties to the receptor binding surface
identified in GDNF (Eketjäll et al., 1999;
Scott and Ibáñez, 2001). In agreement
with previous results, a recent study based
on crystal structure of D3 and
homologous domain modeling of D2 of
rat GFRα1, combined with site-directed
mutagenesis studies, revealed that Phe213
of the MLF triplet,  Arg224 and Arg225
of the RRR triplet and in addition Ile229
generate a putative binding surface for
GDNF (Leppänen et al., 2004).  The
GFRα1 Arg224 and Arg225 as well as a
hydrophobic residue at 229 are fully
conserved between GFRα-receptors,
which suggest that all GFRα-GFL
complexes share these interaction sites
(Leppänen et al., 2004). However, future
studies are needed to identify the
sequence and nature of interaction
between the other GFL-GFRα complexes
and Ret.
Ret activation requires both ligand and
GFRα-receptor binding. A recent
mutagenic analysis of the extracellular
domain of human RET showed that three
of the four N-terminal cadherin-like
domains 1-3 (CLD1-3) are required for
ligand binding, whereas the most
important ligand determinants appeared
to be in CLD1 (Kjaer and Ibáñez, 2003).
Calcium binding to the extracellular
RetCa2+-binding site between CLD2 and
CLD3 is crucial for GDNF- and NRTN-
induced GFL/GFRα/RET oligo-
merization, for RET phosphorylation, to
stabilize the signaling complex and for
the transport of fully maturated Ret to the
plasma membrane (Anders et al., 2001;
Nozaki et al., 1998; van Weering et al.,
1998).
According to the original model by
Jing and co-workers where GFLs/GFRαs
bind and activate Ret, both receptors
should be expressed and interact on the
same cell (Jing et al., 1996). This in cis
model is supported by the overlapping
expression of the Ret receptor and at least
one of the GFRα-receptors in the same
cell population (Golden et al., 1998;
Golden et al., 1999; Rossi et al., 2000;
Widenfalk et al., 1997; Widenfalk et al.,
1999) (Fig. 3A). The ligand can act as a
trophic factor or morphogen when the
preferred ligand for the GFRα/Ret
complex is expressed in cells
complementary to those expressing
GFRα and Ret, for example in the target
organ for innervating neurons (Nosrat et
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al., 1996; Rossi et al., 2000; Trupp et al.,
1997; Widenfalk et al., 1997) or in the
mesenchyme of the developing ureteric
bud (Nosrat et al., 1996; Sainio et al.,
1997; Suvanto et al., 1996). However,
Gfra1 and Gfra2 mRNA levels are high
in brain regions such as in the adult mouse
cortex not found to express Ret (Golden
et al., 1998; Trupp et al., 1997), indicating
different Ret-independent signaling
mechanisms. However, several in vitro
experiments have shown that GFRα-
receptors can be released from the cell
surface by cleavage of the GPI-anchor and
act as soluble receptors presenting the
ligand to Ret located in the membrane of
another cell in trans (Jing et al., 1996;
Klein et al., 1997; Treanor et al., 1996)
(Fig. 3B). GFRα1 has in fact been shown
to be released into the conditioned
medium after lesion of ex vivo cultured
sciatic nerve, suggesting that GFRα1
could be released also in vivo at least as
injury response (Paratcha et al., 2001).
Furthermore, supernatants containing
released GFRα1 from tissue explants
have been shown to transactivate Ret in
the presence of GDNF in sympathetic
neurons (Ledda et al., 2002). Trans-
activation of Ret also occurs in cell lines
after GDNF treatment, even though
GFRα1 is immobilized on beads, on
surface or on other cells (Yu et al., 1998;
Paratcha et al., 2001).
Most GPI-linked proteins are
suggested to be localized to specialized
detergent-resistant membrane fractions,
called lipid rafts. These rafts are reported
to be floating membrane platforms in the
exoplasmic leaflet of the membrane
Figure 3. GFL signaling in lipid rafts (in cis) and outside lipid rafts (in trans). Inactive
RET is located outside rafts but upon stimulation GFRá1 recruits RET by an unknown mecha-
nism to the rafts. Activated RET in lipid rafts is preferentially associated with FRS2, whereas
outside rafts RET is associated with Shc. Adapted from (Airaksinen and Saarma, 2002).
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bilayer that are rich in cholesterol and
sphingolipids (Simons and Ikonen, 1997).
Many intracellular signaling molecules
may be attached to these lipid rafts such
as Src-family kinases (SFK) and small
GTPases (eg. H-Ras), and have been
implicated as signaling platforms for
various transmembrane and GPI-linked
proteins (Saarma, 2001; Simons and
Toomre, 2000). However, the lipid raft
concept is based on biochemical
detergent extraction studies, and no direct
visual evidence of their existence has yet
been presented (Munro, 2003). Reports
based on biochemical studies have shown
that the GPI-linked GFRα1 is localized to
lipid rafts and that GDNF bound to
GFRα1 rapidly recruits Ret from the non-
raft compartment of the cell membrane
into the lipid rafts in cis (Tansey et al.,
2000). Soluble GFRα1 bound to GDNF,
is also able to recruit Ret to lipid rafts in
trans, but in a more sustained manner
which requires Ret activation (Paratcha et
al., 2001) (Fig. 3). There is evidence that
TGF-β acts in a synergistic way with
GDNF to promote the survival of PNS
and some CNS neurons (Krieglstein et al.,
1998). TGF-β may cause clustering of
GFRα1 receptors to lipid rafts and in that
way aids in GDNF recognizing its
receptor (Peterziel et al., 2002). However,
the mechanism by which GDNF-
signalling is assisted by TGF-β is still
unknown.
1.7.2 RET tyrosine kinase activation
Upon ligand binding to GFRα-receptors
and Ret, two transmembrane Ret
molecules dimerize and trans-
phosphorylate cytoplasmic tyrosines. The
cytoplasmic domain of the long isoform
of RET (RET51) contains 18 tyrosine
residues of which 14 are known to be
autophosphorylated,  whereas 12
tyrosines out of 16 are identif ied as
autophosphorylated in the short isoform
of RET (RET9) (Encinas et al., 2004; Liu
et al., 1996). These autophosphorylated
tyrosines serve as docking sites for
various proteins with phosphotyrosine
binding (PTB) motifs or Src-homology 2
(SH2) domains which determine the
pathways leading to survival, neurite
outgrowth, differentiation etc. (Kurokawa
et al., 2003). Several important cell
signaling cascades are activated by RET
transphosphorylation. Phosphorylated
tyrosine 905 binds GRB7 (growth factor
receptor- bound protein 7) and GRB10,
pTyr1015 binds PLCγ (phospholipase
Cγ), and pTyr1096 only present on RET51
isoform binds GRB2. The phosphorylated
tyrosine 1062 present in both isoforms
serves as a docking site for many effector
proteins including Shc (SH2 domain
protein C1), FRS2 (FGF receptor
substrate), IRS1 (insulin reseptor
substrate 1) and DOK4/5 (downstream of
tyrosine kinase 4/5), and is a crucial
docking site for signaling during
embryogenesis and carcinogenesis
(reviewed by Ichihara et al., 2004; Manié
et al., 2001; Takahashi, 2001) (Fig 4). This
tyrosine includes a PTB binding motif
NXXpY (Kurokawa et al., 2003).
Enigma, a protein consisting of a PDZ-
domain and three LIM-domains, can bind
to Tyr1062 in RET9 but poorly to RET51
regardless of its phosphorylation status
(Borrello et al., 2002). Enigma may be
involved in the clustering and recruitment
of RET to the plasma membrane (Durick
et al., 1996). GDNF induces intracellular
signaling cascades in Ret which include
RAS/mitogen-activated protein kinase
(MAPK) and the phosphatidylinositol 3-
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kinase (PI3K)/AKT, p38 MAPK and c-
Jun N-terminal kinase (JNK), pathways
known to be activated also by other
protein kinases.  Activation by GDNF of
both the MAPK and the PI3K/AKT
pathways requires binding of Shc adaptor
protein to the pTyr1062 of RET which
further associates with GAB1/2 and
GRB2 to activate the RAS/ERK or the
PI3K/AKT pathways. The MAPK
signaling pathway mediated by SHC
binding to pTyr1062, results in activation
of downstream targets GRB2+Sos, Ras,
ERK1/2 and transcription factor cAMP
responsive element (CREB), whereas
FRS2 binding to pTyr1062 results in
activation of SHP2 tyrosine phophatase,
ERK and CREB (Hayashi et al., 2000).
FRS2 is a lipid anchored docking protein
proposed to activate the MAPK signaling
cascade mainly after recruiting Ret to the
lipid rafts by GDNF/GFRα1, whereas Shc
may be associated to activated Ret outside
the lipid raft in order to keep balance
Figure 4. Intracellular pathways through activated RET and sites for activating muta-
tions in RET. Transphosphorylation of intracellular tyrosines in RET generate binding sites
for various adapter molecules which specify the down-stream signaling pathway and biologi-
cal response.
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between the two competing signaling
pathways (Kurokawa et al., 2003;
Paratcha and Ibáñez, 2002) (Fig. 3). The
binding of FRS2 is suggested to be
necessary for sustained MAPK activation
and neuronal differentiation. The MAPK
pathway is important for neurite
outgrowth and survival, neuronal
differentiation and ureteric epithelial
branching morphogenesis (Califano et al.,
2000; Fisher et al., 2001; De Vita et al.,
2000).
 Recruitment of Shc to pTyr1062 also
results in the phosphorylation PI3K and
downstream activators serine-threonine
kinase Akt (protein kinase B) and focal
adhesion kinase (FAK) activation which
both activate transcription factor NFκB.
pTyr1096 seems to activate only the
PI3K/AKT pathway although it binds
GRB2 (Bessett et al., 2000). The PI3K/
AKT pathway has proven to be important
in neurite lamellopodia formation,
neuronal survival, neurite outgrowth and
cell proliferation (Fukuda et al., 2002;
Sariola and Saarma, 2003). Nerve growth
cones are enriched in Src family kinases
and the activation of Ret by ligand
generates Src-SH2 docking site on Ret
irrespective of the localization of the
receptor (Tansey et al., 2000). Recently,
the major binding site for c-Src was
localized to pTyr981 in Ret (Encinas et
al., 2004) (Fig. 4). C-Src has been shown
to be essential for GDNF- but not NGF-
induced maximal neuronal survival and
differentiation signaling (Encinas et al.,
2001), which implies a RET specif ic
neuronal SFK response.
Lamellopodia formation in neurons by
GDNF is controlled through at least two
different signaling pathways, via tyrosine
1062 and serine 696 in Ret (Fukuda et al.,
2002). The phosphorylation of Ser696
was shown to be mediated by protein
kinase A (PKA) through elevated
intracellular cAMP-levels regulated by
unknown G-protein-linked receptors.
This result suggests cross-talk with Ret
and G-protein-linked receptors in the
regulation of cytoskeletal structures.
Furthermore, cross-talk between Ret and
TrkA receptor has been observed, as NGF
promoted Ret phosphorylation without
GFL stimulation in sympathetic postnatal
neurons (Tsui-Pierchala et al., 2002b).
Among RET autophosporylated tyrosines
and phosphorylated serines/threonines,
additional important signaling and
inhibiting pathways mediated by RET are
likely to be discovered in the future.
1.8 RET-independent GFL/GFRα
signaling
In many brain areas especially in the
forebrain, cortex and inner ear, GFRα
receptors are more widely expressed than
Ret (Kokaia et al., 1999; Trupp et al.,
1997; Ylikoski et al., 1998), which
suggests that GFLs can signal
independently of Ret in collaboration
with other transmembrane receptors.
GDNF treatment of a cell line lacking Ret
but expressing GFRα1 resulted in Src
family kinase (SFK)-dependent CREB
phosphorylation, leading to a fast
upregulation of transcription factor c-fos
mRNA (Trupp et al., 1999). Additionally,
GDNF was shown to induce SFK
activation, PLCγ, CREB and MAPK
phosphorylation in DRG neurons derived
from homozygous Ret-deficient embryos
and in Ret-negative cell lines (Poteryaev
et al., 1999). However, the mechanisms of
how intracellular SFKs are activated by
GDNF binding to extracellular GFRα1
remained unclear. The f inding that
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exogenous GDNF is able to increase
branching morphogenesis in kidney
explants from Ret-/- mice led to the
discovery of an alternative signaling
receptor for GDNF, namely the receptor
tyrosine kinase Met (Popsueva et al.,
2003). Hepatocyte growth factor (HGF),
the ligand for Met, induces scattering,
tubule formation and chemotaxis of Met
expressing dog epithelial MDCK cells.
GDNF was shown to activate Met and
induce tubulogenesis through GFRα1 and
SFK in MDCK cells which lack
endogenous Ret receptor (Popsueva et al.,
2003). However, the activation of Met
through SFK was not mediated by direct
binding of GFRα1/GDNF to Met, and the
role for GDNF-induced Met activation in
vivo is still unresolved.
In a recent study, exogenous
GDNF was able to induce Schwann cell
migration and axonal growth of
hippocampal and cortical neurons from
Ret-deficient mice known to express
GFRα1 and the neural cell adhesion
molecule NCAM (Paratcha et al., 2003).
GDNF was shown to bind NCAM with
high affinity in the presence of GFRα1
and to rapidly activate cytoplasmic SFK,
Fyn as well as focal adhesion kinase
(FAK) in cells lacking Ret. This suggested
that NCAM is an alternative binding and
signaling receptor for GDNF and GFRα1.
Furthermore, GFRα1 was able to
associate with NCAM in the absence of
GDNF and downregulate NCAM-
mediated cell adhesion, indicating a
ligand independent role for GFRα
receptors. Interestingly, NCAM knock-
out mice and heterozygous GDNF-
deficient mice have impairments in
spatial learning (Cremer et al., 2000;
Gerlai et al., 2001). Moreover, mice
lacking GFRα2 have impaired behavioral
flexibility and recall in different memory
and learning tasks (Võikar et al., 2004).
These results indicate that GFLs and
GFRαs can regulate neuronal synaptic
plasticity through NCAM in the
developing and postnatal brain. The
survival effect of GDNF on dopaminergic
neurons could be inhibited by using
blocking antibodies to NCAM, which
further supports the importance of
NCAM in GDNF signaling (Chao et al.,
2003). Furthermore, there may be
interplay between Ret and NCAM
signaling by GFLs in cells expressing
both receptors or even between adjacent
recepors expressed by different cells in
trans.
1.9 RET in disease
1.9.1 Loss-of-function mutations in
RET cause developmental
enteric nervous system defects
Hirschsprung disease (HSCR) or
congenital aganglionosis of variable
segments of the large bowel in humans is
a relatively common disorder (1/5000
births), leading to intestinal obstruction
or chronic constipation usually already at
birth (reviewed by Parisi and Kapur,
2000). Most HSCR cases are sporadic,
with 10-15% being familial forms.
Mutations in different genes, many of
which are involved in the RET and
endothelin signaling pathways, have been
associated to HSCR. Mutations in the
RET gene accounts for 50% of the
familial cases and for 10-20% of the
sporadic cases. These mutations
constitute deletions, insertions, missense,
nonsense, and frameshift mutations. On
the basis of the localization of a RET
mutation, these can be divided into two
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main types types; those that impair the
RET cell surface expression and those
that impair the activation of the RET
tyrosine kinase (reviewed by Iwashita et
al., 2001; Manié et al., 2001; Takahashi,
2001). All these mutations are likely to
affect the GDNF-mediated enteric
precursor cell migration from the neural
crest, and they are believed to be one
causative means in HSCR. Furthermore,
premature cell death of enteric neural
crest cells in HSCR may be caused by a
recently discovered death pathway
mediated by binding of caspase-3 directly
to the kinase domain of RET which
mediates cell self-destruction in the
absence of impaired ligand activation
(Bordeaux et al., 2000). Germline
mutations in the genes encoding for
GFRα1-GFRα4 are not major
contributors to HSCR (Borrego et al.,
2003). Although mutations in the GDNF
and NRTN genes have been found in only
a minority of HSCR cases, only a few
mutations affect the ligand binding to
GFRα-receptor (Eketjäll and Ibáñez,
2002). However, they may in conjuction
with other lesions contribute to the
pathogenesis of HSCR.
1.9.2 Gain-of-function mutations in
RET promote thyroid tumors
Ret mRNA is expressed already in neural
crest cells of the developing nervous
system (Pachnis et al., 1993). High
expression of RET is also detected in
many tumors of neural crest origin (Miya
et al., 1992; Nakamura et al., 1994;
Santoro et al., 1990). Germline missense
mutations in the RET gene cause multiple
endocrine neoplasia type 2A and 2B
(MEN2A and MEN2B) syndromes and
familial medullary thyroid carcinoma
(FMTC) (Table 3). The MEN2A
syndrome is characterized by multifocal
and bilateral medullary thyroid
carcinoma (MTC) of the parafollicular C-
cells, pheochromocytoma (pheo, 50%) of
the adrenal medulla and
hyperparathyroidism (20%), all with a
neural crest origin. MEN2A is the most
common form of MEN2 syndromes
(90%) with a clinical onset below 20 years
of age. MEN2B accounts for
approximately 5% of all MEN2 cases but
is associated with a more aggressive
disease progression and an earlier tumor
onset (<10 years of age). MEN2B patients
suffer from MTC, pheochromocytoma
(50%), intestinal and mucosal
ganglioneuromatosis, musculoskeletal
abnormalities including marfanoid
features, and a male reproductive defect
(reviewed by Bachelot et al., 2002;
Ponder, 1999). The only disease
phenotype in FMTC is bilateral,
multifocal MTC with a later onset than in
MEN2A and MEN2B and with a good
prognosis. Missense mutations involved
in the RET gene of MEN2A and FMTC
are mainly clustered to exons 10 and 11,
coding for the extracellular cysteine rich
juxtamembrane domain. Cysteine
substitutions in FMTC families occur
frequently in codons 609, 611, 618, 620,
630 and 634 (Ponder and Smith, 1996).
FMTC mutations are also identified in the
tyrosine kinase domain of RET at codons
768, 790, 791, 804 and 891. The most
common mutation found among MEN2A
families is Cys634 substituted by Arg
(52%) or Tyr (26%), but mutations in
cysteines 609, 611, 618, 620 and 630 are
also known to cause MEN2A. MEN2B is
mainly caused by a single substitution of
a methionine residue at position 918 to a
threonine (95%) in the tyrosine kinase
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domain, but rare MEN2B cases with
mutations in codons 883 and 922 have
also been reported. Approximately 75%
of the diagnosed MTCs are sporadic with
no familial background and 30-70% of
these are reported to contain a somatic
RET mutation which most frequently is
the M918T mutation also found in
MEN2B families (reviewed by Eng and
Mulligan, 1997).
Papillary thyroid carcinoma (PTC) is
a sporadic and somatic tumor derived
from follicular epithelial cells of the
thyroid. PTC is frequently associated with
chromosomal rearrangements joining
together the 5´end of a heterologous gene
to the cytoplasmic tyrosine kinase domain
of RET, generating a chimeric oncogene
designated RET/PTC (reviewed by
Santoro et al., 1999; Takahashi, 2001).
RET is normally silent in thyroid
follicular cells but production of RET/
PTC oncoproteins can be driven by the
promoter of the fusion partner. The
MEN2 type MEN2A MEN2B FMTC 
Medullary thyroid 
cancer
70-80%
early onset 
(age)
100%
earliest onset (age) 
100%
late onset 
Pheochromocytoma 50%
C634any 
50% - 
Parathyroid  
hyperplasia
20-30%
C634R 
- - 
Other phenotypes - Mucosal neuromas 
Musculoskeletal 
abnormalities 
Impotence 
Infertility 
-
RET mutation Extracellular 
C634 85% 
Intracellular or TK2* 
M918T (95%) ** 
Cys-rich domain or 
TK1*
C634other (not R 30%) 
Table 3. Clinical features associated with MEN2 syndromes
*TK1 and TK2; Tyrosine kinase domain
** Most somatic RET mutations in MTC (>70%) are of MEN2B (M918T) type
chimeric proteins do not usually contain
a signal sequence for membrane
transport. Thus the dimerized RET/PTC
proteins remain in the cytoplasm,
activating RET specif ic signaling
pathways leading to tumorigenesis. To
date, 9 different fusion partner genes have
been found to be associated with the RET
kinase domain in RET/PTC
rearrangements in which the RET/PTC1
and RET/PTC3 are the most frequently
found with activating genes H4 and ELE1
(Pierotti et al., 1996; Santoro et al., 1994).
The RET/PTC rearrangements are found
with a highly variable frequency among
different countries and populations,
suggesting that genetic background and
environmental factors play a role in their
birth. Additionally, RET/PTC is likely to
develop in the thyroid gland as a direct
consequence of radiation exposure and
the ability of thyroid follicular cells to
concentrate radioactive iodine (Santoro et
al., 2000).
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1.9.3 Oncogenic Ret signaling
The signaling mechanisms for MEN2A,
MEN2B and RET/PTC oncoproteins
have been extensively studied in murine
fibroblasts over-expressing respective
oncoproteins. These are well known tools
used in cancer studies because of their
capacity to form foci in culture (Asai et
al., 1995; Santoro et al., 1994; Santoro et
al., 1995). A cell line derived from a
metastatic MTC tumor heterozygous for
a RET MEN2A mutation, known as TT,
and a rat pheochromocytoma cell line,
PC12, are also widely used for RET in
vitro oncogenesis studies (Borrello et al.,
1995; Carlomagno et al., 1995). In
contrast to the ligand-induced Ret, the
MEN2 and RET/PTC proteins are
constitutively active. Upon activation, the
cysteines in the extracellular Cys-rich
region form intermolecular disulf ide
bridges in wild type RET, whereas the
unpaired cysteines in MEN2A RET are
believed to form intramolecular covalent
disulfide bonds. This leads to constitutive
dimerization of two RET MEN2A
molecules and thereby constitutive
transphosphorylation of tyrosines in the
kinase domain (Santoro et al., 1995). The
activation is thought to resemble that of
the ligand induced RET activation.  The
weaker transforming activity by FMTC
and some MEN2A mutations is thought
to depend on a misfolding of the
oncoproteins which results in an impared
cell surface expression (Chappuis-
Flament et al., 1998; Takahashi et al.,
1999). The mechanism of MEN2B RET
activation differs from that of MEN2A, as
MEN2B and intracellular FMTC proteins
are constitutively active as monomers
(Santoro et al., 1995). The tyrosine kinase
domain of RET is highly conserved
among other tyrosine kinases and
especially those motifs that are involved
in ATP-binding, catalytic activity and
substrate binding (Hubbard and Till,
2000; Scott, 2002). The
autophosphorylation of tyrosines in the
activation loop induces drastic changes in
the conformation of the activation loop
(Kawamoto et al., 2004). The MEN2B
M918T mutation is thought to change the
substrate specificity of the activation loop
in the RET kinase domain, as Src family
and most others non-receptor tyrosine
kinases also have a threonine residue at
this position (Zhou et al., 1995; Santoro
et al., 1995; Songyang et al., 1995).
Accordingly, c-Src is phosphorylated and
associated with RET oncoproteins
(Melillo et al., 1999). Additionally,
dominant-negative Src has been shown to
reduce tumorigenic activation in a tumor
caused by a homologous MEN2B
mutation in the MET receptor tyrosine
kinase (Nakaigawa et al., 2000). These
studies suggest a critical role for Src in
MEN2B mediated cell transformation.
The distinct activities of MEN2A and
MEN2B RET oncoproteins are supported
by phosphopeptide mapping analysis,
downstream target protein activation and
differential display analysis of genes that
are induced or suppressed by MEN2A
and MEN2B proteins (Bocciardi et al.,
1997; Liu et al., 1996; Murakami et al.,
1999; Murakami et al., 2002; Salvatore et
al., 2001; Watanabe et al., 2002). The
more aggressive phenotype in MEN2B
might be explained by the stronger
activation of the JNK-pathway through
the association of pY1062 with Dok1 and
Nck1 (Murakami et al., 2002).
Upregulation of the stanniocalcin I
(STC1) gene in MTC of MEN2B patients
suggest that stanniocalcin might be
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involved in the skeletal phenotype in
MEN2B (Watanabe et al., 2002). GDNF
is further reported to enhance the
phosphorylation status of the MEN2A
and MEN2B oncoproteins (Bongarzone
et al., 1998; Borrello et al., 1995;
Carlomagno et al., 1998; Mograbi et al.,
2001). Tyrosine 1062 activation and
subsequent binding of Shc and FRS2
adaptor proteins have both in vivo and in
vitro proven to be crucial for the
activation of PI3K/Akt and MAPK
pathways in MEN2A, MEN2B and RET/
PTC oncogenic signaling (Asai et al.,
1996; Hayashi et al., 2000; Iwashita et al.,
2000; Kurokawa et al., 2001; Ludwig et
al., 2001; Melillo et al., 2001; Salvatore
et al., 2000; Segouff in-Cariou and
Billaud, 2000; De Vita et al., 2000). In
addition, a double substitution of Y900
and Y905 to phenylalanine in RET
MEN2A completely abolished the kinase
activity, whereas the kinase activity and
transforming activity was impaired in the
MEN2A mutants Y806F and Y809F
(Kawamoto et al., 2004).
 RET9 and RET51 isoforms appear to
be equally co-expressed in MTC and
pheochromocytomas (Myers et al., 1995),
although the oncoproteins of RET
isoforms have different transforming
activities. In vitro, the RET51 MEN2B
and FMTC oncoproteins have been
reported to have a more potent
transforming ability than RET9 and can
induce a more robust neurite outgrowth
in PC12 cells (Iwashita et al., 1999; Pasini
et al., 1997; Rossel et al., 1997).
To date, the primary treatment of
tumors developed in MEN2 syndromes
and sporadic thyroid tumors (MTC and
PTC) is restricted to surgical removal of
the tumor or gland. Specific molecules
known to downregulate RET activation
have been suggested to function as
potential therapeutic agents for these
endocrine tumors. Grap-2, a novel RET-
binding protein has been shown to
downregulate NF-κB activation and
specifically reduce the focus formation
ability induced by oncogenic RET
(Ludwig et al., 2003).  PP1, a pyrazolo-
pyrimidine inhibitor was shown to induce
oncoprotein MEN2A and MEN2B
degradation and therefore been proposed
as an efficient drug in the treatment of
MTC tumors (Carniti et al., 2003).
Indolocarbazole derivatives, CEP-701
and CEP-751 are able to effectively block
RET phosphorylation and cell growth in
MTC cell culture and xenographs (Strock
et al., 2003). Furthermore, a specif ic
orally available anilinoquinazoline
tyrosine kinase inhibitor can effectively
block RET oncoprotein phosphorylation
in cell lines and RET/PTC3-induced
tumor formation in nude mice
(Carlomagno et al., 2002). It may thus be
a promising drug in the treatment of RET-
induced tumors, especially medullary
thyroid carcinoma which responds poorly
to conventional chemotherapeutics.
1.9.4 Proposed mechanisms for the
tissue-specific tumor formation
in MEN2
One major unresolved question
concerning the roles of RET MEN2A and
MEN2B in the development of endocrine
tumors is why tumor formation is
restricted only to distinct tissues in the
syndromes, although the mutated
heterozygous RET is expressed in many
other types of cells during development
(Pachnis et al., 1993; Tsuzuki et al.,
1995).
Review of the literature
30
Several possible explanations have
been proposed. RET MEN2 activation in
cell lines derived from different origin has
been shown to lead to distinct cellular
responses suggesting that RET MEN2
may be capable of tumor formation only
in distinct cells (Califano et al., 1996;
D’Alessio et al., 1995; Rizzo et al., 1996).
Takahashi and co-workers suggested that
co-expression of GFRα-receptors would
interfere with the dimerization of at least
MEN2A proteins and therefore lead to
reduced and controlled signaling of RET
in tissues co-expressing GFRα and RET
(Kawai et al., 2000). In agreement with
this, GFRα1 was co-immunoprecipitated
with MEN2A RET in the presence of
GDNF in a cell line transfected with
MEN2A RET and GFRα1 cDNAs
(Mograbi et al., 2001). Leukocyte
common antigen-related protein (LAR),
a cell surface protein-tyrosine
phosphatase, was shown in vitro if
overexpressed to reduce the constitutive
tyrosine autophosphorylation and kinase
activity of RET MEN2A and MEN2B
proteins by interfering with the
dimerization of RET (Qiao et al., 2001).
Thus, it seems likely that expression of
certain cell surface proteins in affected
cells can modify the clinical phenotypes
of MEN2 syndromes by impairing the
RET dimerization. Interestingly, the LAR
gene is localized to a region in the short
arm of chromosome 1 known to be
frequently deleted in tumors of neuro-
endocrine origin (Jirik et al., 1992;
Mulligan et al., 1993).
Furthermore, similarly to wild type
RET, MEN2A RET was shown to
promote the survival of neuroendocrine
cells in the presence of GDNF and
GFRα1, but triggered apoptosis when
GDNF/GFRα1 was omitted (Mograbi et
al., 2001). GDNF has also been shown to
inhibit the proliferation of an embryonic
carcinoma cell line NT2/D1 with an
accompanying increase in levels of
cyclin-dependent kinase inhibitor
p27kip1, leading to a growth arrest and
subsequent neuronal differentiation
(Baldassarre et al., 2002). This indicates
that at least those neural crest-derived cell
lineages that co-express RET MEN2A
and GFRα1 are able to respond to
endogenous GDNF stimulation by
differentiation rather than proliferation
and are therefore able to develop
normally.
Endocrine cells affected in MEN2
syndromes might be more susceptible to
tumor formation caused by inactivation of
the tumor suppression system. The
retinoblastoma susceptibility gene (Rb)
product is a tumor suppressor inactivating
E2F transcription factor that is known to
be important for activating genes involved
in cell-cycle progression (Harbour and
Dean, 2000). Interestingly, Rb+/- mice
developed MEN2-like syndromes with
tumors of the thyroid C-cells, adrenal
gland, intermediate lobe of the pituitary
and parathyroid (Nikitin et al., 1999).
Furthermore, some Rb +/- mice showed
a missense mutation in the RET gene
corresponding to human MEN2A/FMTC
cysteine rich domain (Coxon et al., 1998).
MTC-samples from the corresponding
mice did not stain for Rb, which suggests
a multistep progression in the formation
of MTC. However, RB downregulation in
human endocrine tumors has not yet been
clearly demonstrated.
Recently, the constitutively
phosphorylated tyrosine 1062 in
oncogenic forms of RET/PTC has been
shown to transmit not only mitogenic, but
also proapototic signals in rat thyroid
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epithelial cells by downregulation of the
antiapototic protein Bcl-2 and
upregulation of  the apoptotic protein Bax
through the Ras/ERK pathway
(Castellone et al., 2003). Thus it might be
possible that cells involved in MEN2
syndromes have aquired a lower threshold
for malignancy than other cells through
their tendency to escape the apoptotic
pathway.
1.9.5 RET MEN2 mutations in
transgenic mice models
Several transgenic mice models
expressing the corresponding human
MEN2A or MEN2B RET mutation under
tissue-specif ic promoters have been
created in order to address issues
concerning the role of RET in the
pathophysiology of MTC and
sympathoadrenal tumors (Acton et al.,
2000; Kawai et al., 2000; Michiels et al.,
1997; Reynolds et al., 2001; Smith-Hicks
et al., 2000; Sweetser et al., 1999).
Transgenic mice expressing multiple
copies of RET9 or RET51 MEN2A or
MEN2B in thyroid C-cells developed C-
cell hyperplasia and subsequent bilateral
MTC accompanying high levels of serum
calcitonin (CT) (Acton et al., 2000;
Michiels et al., 1997). However, tumor
phenotype was shown to differ between
transgene copy lines. Since transgenic
mice expressing the corresponding wild
type allele for RET did not develop
tumors, it was evident that overexpression
of RET51 was not responsible for the
tumors found in the RET mutant mice
(Reynolds et al., 2001). Furthermore,
tumors were not found in tissues
expressing the transgenic MEN2 RET but
co-expressing Gfra1, Gfra2 or Gfra3
(Kawai et al., 2000). In addition, in
western blot analysis disulfide-linked
MEN2A homodimers were detected in
non-reducing conditions from MTC
tissue, but not from other tissues
expressing the MEN2A-transgene
(Michiels et al., 1997), suggesting that
RET transgene was not able to form trans-
signaling dimers in other tissues.
In a knock-in MEN2B mouse model,
the M919T RET mutation corresponding
to the human M918T was introduced to
the mouse genome using the Cre/loxP
site-specific recombination (Smith-Hicks
et al., 2000). The heterozygous RetMEN2B
knock-in mice displayed bilateral C-cell
and chromaff in cell hyperplasia
resembling those features found in human
disease. The homozygous mice displayed
a more severe thyroid and adrenal
phenotype (pheochromocytoma),
ganglioneuromas of the adrenal medulla,
enlargements of the adrenal associated
sympathetic ganglia and male infertility
due to unknown mechanism. However,
thyroid C-cell hyperplasia never
developed into MTC. Surprisingly, the
RetMEN2B homozygous mice did not show
any developmental abnormalities,
suggesting that GFL signaling through
RetMEN2B must be basically normal or then
the RetMEN2B introduced change in
substrate specif icity does not impair
normal development of kidneys or ENS.
Importantly, RetMEN2B mice containing
one Ret kinase-deficient allele did not
show any of the characteristics found in
RetMEN2B homozygous mice. This
demonstrates that the ganglioneuromas
and male infertility are due to a gene
dosage effect rather than a loss-of-
function effect (Smith-Hicks et al., 2000).
MTC tumor penetrance appears to
differ signif icantly between different
mouse background strains (Cranston and
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Ponder, 2003). This important finding
indicates that genetic background could
modulate the tumor onset. As tumor
phenotypic expression varies both within
and between MEN2 families, it would be
of importance to identify and elucidate
the effects of modifier genes involved in
this disease. Furthermore, the relevance
of the latter finding must be taken into
consideration when studying the effect of
other oncogenes. Crossing MEN2-
transgenic mice with mutant mice
deficient in a RET signaling component,
should reveal the contribution for the
signaling molecule in transforming
capacity. Furthermore, these mice will be
important tools for testing
pharmaceutical compounds which might
inhibit RET oncogenic function.
1. 10 Endocrine organs relevant in RET
signaling
The endocrine system is based on a
number of glands which synthesize and
secrete hormones into circulating blood
to act on target tissues. Together with the
nervous- and immune systems, the
endocrine system regulates the internal
physiological homeostasis in the body by
making appropriate adaptive changes to
internal and external stimuli. The major
endocrine glands are the pituitary, the
thyroid, the parathyroid, the adrenal, the
pancreas (islets of Langerhans), ovary and
testis. Hormones can be chemically
divided into three classes: the amino acid-
tyrosine-derived hormones, peptide and
protein hormones and cholesterol-derived
steroid or steroid-like hormones.
Hormones are either released to the
extracellular space to act on the same cell
(autocrine hormones) or on neighboring
cells (paracrine hormones) or released
into the bloodstream. Amino acid and
peptide/protein hormones act by binding
to specific tyrosine kinase- or G-protein-
coupled receptors on the target-cell
surface, whereas steroids and steroid-like
hormones are recognized by intracellular
receptors.
1.10.1 The thyroid gland
The structures that contribute to the
mature thyroid gland, the follicular cells
and the parafollicular cells, are derived
from different pharyngeal regions during
embryonic development. The thyroid
gland forms from cells of two different
origins. The posterior migration of cells
of the diverticulum from the ventral floor
of the pharynx and the medial and ventral
migration of the ultimobranchial bodies
from the fourth pharyngeal pouch, fuse to
form the mature thyroid gland (Fontaine,
1979; Pearse and Carvalheira, 1967;
Pearse and Polak, 1971).  The
parathyroids derived from the third
pharyngeal pouch, migrate lateral to the
thyroid gland (Manley and Capecchi,
1995). The parafollicular C-cells are
derived from the ultimobranchial bodies
that are embryonic structures derived
from the pharyngeal pouch and the vagal
neural crest ectoderm. Most of the thyroid
follicular cells are derived from the
endodermal diverticulum whereas a
minority of the follicular cells is derived
from ultimobranchial bodies (Reynolds et
al., 2001). The thyroid develops into two
distinct lobes on either side of the trachea
and larynx connected by a narrow isthmus
of thyroid tissue at the midline. The
parafollicular C-cells are interspersed in
small groups between the follicles in the
intermediate part of the thyroid lobes.
Capillaries and lymphatic vessels
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surround the follicles and postganglionic
sympathetic nerve f ibers from the
superior and middle cervical ganglia
control the blood flow through the thyroid
gland.
The characteristic features of follicle
cells are to concentrate iodine from the
bloodstream and produce the hormones
thyroxine (T
4
) and its bioactive
triiodothyronine (T
3
) from thryroglobulin
which stimulate cell metabolism and are
essential for body growth. The
parafollicular C-cells secrete calcitonin
(CT) which is a peptide of 32 amino acids.
Exogenous calcitonin hormone binds to
specific CT receptors on bone osteoclasts
and suppresses the activity of osteoclasts
to mobilize calcium from bone and thus
may have a stimulatory effect on bone
formation (Lin et al., 1991; Nicholson et
al., 1986). Secretion of calcitonin is
stimulated by elevation in serum Ca2+
levels which at the same time suppress
secretion of parathyroid hormone (PTH),
the main hormone for calcium resorption.
Specif ic calcium-sensing G protein-
coupled receptors contribute to the
calcitonin secretion in C-cells, whereas
similar receptors in parathyroid cells
contribute to the inhibition of parathyroid
hormone secretion (Freichel et al., 1996).
Although calcitonin is effectively used to
treat osteoporosis, the normal
physiological role of calcitonin in bone
formation remains unclear (Civitelli et al.,
1988). Surprisingly, mice lacking the CT/
CGRPα-gene or its receptor show normal
bone resorption but increased bone mass
due to increased bone formation (Dacquin
et al., 2004; Hoff et al., 2002), which
suggests an unrecognized effect of CT/
CGRP in bone formation postnatally.
The role for Ret, GFRα-receptors and
GFLs in the development of the thyroid
is unclear. Ret mRNA has been localized
to the endoderm of branchial arches and
thyroid C-cells probably express Ret
mRNA already as neural crest progenitors
in the ultimobranchial body (Pachnis et
al., 1993). The expression of Ret is
reduced postnatally in the thyroid
(Golden et al., 1999) but is, however,
detected in the C-cells of normal adult
thyroid (Belluardo et al., 1999; Tsuzuki
et al., 1995). Gfra1 and Gfra2 mRNA has
not been detected in thyroid C-cells but
Gfra1 was present in thyroid follicular
cells (Belluardo et al., 1999; Golden et al.,
1999).  High RET expression together
with elevated calcitonin levels has been
localized in thyroid C-cell hyperplasia
and consequently in MTC (Golden et al.,
1999; Santoro et al., 1990; Takaya et al.,
1996). GDNF mRNA has not been
detected in the thyroid gland (Belluardo
et al., 1999). However, NRTN was present
in some thyroid follicular cells (Belluardo
et al., 1999). No expression data of Gfra3
mRNA in thyroid is available, but ARTN
mRNA has been detected by Northern
blot from thyroid gland (Baloh et al.,
1998b). Transcripts for Ret, Gfra1, GDNF
and NRTN were not found in the
parathyroids of the developing mouse
(Golden et al., 1999). However, Gfra2 was
highly expressed in the developing mouse
parathyroid from E12 to E18 (Golden et
al., 1999).
1.10.2 The adrenal gland
The adrenal gland consists of two main
parts, the medulla and the cortex. The
medullary chromaff in cells originate
from the trunk neural crest or
sympathoadrenal (SA) cell lineage which
also give rise to sympathetic neurons
(reviewed by Anderson, 1993). During
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embryonic development, the SA cells
migrate to the dorsal aorta to form the
sympathetic primordium. The cells
differentiate to cathecholaminergic
tyrosine hydroxylase positive neuronal
progenitor cells and remigrate to their
final destinations in response to different
cues from the dorsal aorta. The cells that
migrate to the adrenal medulla loose their
neuronal traits and differentiate into
chromaff in cells. The adrenal cortex
originates from mesothelial cells located
at the cranial end of the mesonephros. The
cortex is divided into three zones on the
basis of cell types which release
aldosterone, glucocorticoids and
androgens. The adrenal medulla
comprises about 20% of the adrenal gland
and is composed of catecholamine-
producing chromaffin cells, ganglion
cells, venules and capillaries. Two distinct
sets of chromaffin cells are found in the
medulla: those that secrete epinephrine
(85%) and those that secrete
norepinephrine synthesized from
phenylalanine. The release of
catecholamines in concert with
glucocorticoids prepares the body for
maximum use of energy through an
increase in blood pressure, vasodilation,
increased heart rate and rate of breathing.
Each chromaffin cell is innervated by a
cholinergic, pregangliotic sympathetic
neuron which releases acethylcholine,
which stimulates the chromaffin cells to
release catecholamine.
Expression of Ret mRNA is observed
in the SA cells aggregating at the dorsal
aorta (Pachnis et al., 1993). While Ret
continues to be expressed in the
developing sympathetic neurons, its
expression is very low in the developing
mouse adrenal and in adult adrenal cortex
(Schober et al., 2000). Nerve fibers in the
adult adrenal cortex are reported to
express Gfra1 and Gfra2 but not Ret,
whereas ganglion cells in the adrenal
medulla express Gfra1 and Ret (Schober
et al., 2000). However, chromaffin cells
express high levels of Gfra2 and its ligand
Nrtn but no Ret (Golden et al., 1999;
Schober et al., 2000; Widenfalk et al.,
1997). GDNF mRNA is expressed from
E16 onward by rat chromaffin cells, but
its function in the adrenal medulla is still
enigmatic. GDNF is however suggested
to offer trophic support for sensory
neurons innervating chromaffin cells
(Krieglstein et al., 1996).
 Pheochromocytomas (pheos) are
benign tumors originating from adrenal
chromaffin cells of which approximately
80% are sporadic and 20% familial.
Sporadic pheos are rarely associated with
activating mutations in RET although the
wild-type RET gene is frequently
expressed in pheos (Miya et al., 1992;
Santoro et al., 1990; Takaya et al., 1996).
Additionally, the level of RET
phosphorylation in pheos is comparable
to that of MEN2 constitutively activated
RET (Le Hir et al., 2000). Moreover,
levels of GDNF transcripts are several
times higher in pheos than in normal
adrenals but the Gfra1 transcript remains
low in normal adrenal and pheos (Le Hir
et al., 2000). The contribution for GDNF
in pheos is thus unclear.
1.10.3 The pituitary gland
The hypothalamopituitary axis plays a
central role in the endocrine system. It
organizes appropriate hormonal response
from the brain in response to changes in
the external environment by positive/
negative feedback. The pituitary has three
functional components the anterior lobe
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(adenohypophysis), consisting of
glandular epithelial tissue and the
intermediate lobe, which derive from
evagination of the ectoderm of the
oropharynx or the Rathke´s pouch (Amar
and Weiss, 2003). The posterior lobe (the
neurohypophysis), is derived from a
ventral extension of the dienchephalon,
the infundibulum. The adenohypophysis
is rich in secretory cells which release
different hormones regulated via the
hypothalamic portal vessel system. The
acidophilic  somatotrophs secrete growth
hormones (GH) and the mammotrophs
prolactin (PRL) whereas the basophilic
thyrotrophs secrete thyroid stimulating
hormone (TSH), corticotrophs
adrenocorticotrophin (ACTH), and the
gonadotrophs luteinizing and follicle
stimulating hormones (LH and FSH). The
neurohypophysis secretes two hormones,
vasopressin and oxytosin originally
released from neurons whose cell bodies
are located in the hypothalamus. The
intermediate lobe is rudimentary in
humans but produces several hormones
whose significance is only now being
established.
In the mouse embryonic pituitary,
transcripts for Ret, Gfra1, Gfra2 and their
respective ligands have been detected
between E12 to E16 (Golden et al., 1999).
In the adult rat pituitary, GDNF has been
detected in the intermediate lobe (Saland
et al., 2000) but it is also expressed
together with Ret and Gfra1 in anterior
and posterior lobes (Urbano et al., 2000).
GDNF in the anterior lobe was detected
by immunohistochemistry in
corticotrophs and gonadotrophs, while
Ret was mainly expressed by
somatotrophs (Urbano et al., 2000). In
human pituitary, most of the
somatotrophs express both GDNF and
RET (Japon et al., 2002), suggesting
possible autocrine regulation of
somatotroph cell growth or/and function.
Furthermore, a strong immunostaining
for RET, GDNF or/and GFRα1 was found
in different types of pituitary tumors
secreting GH or ACTH (Japon et al.,
2002), implying that GDNF and RET
could be involved in the pathogenesis of
pituitary tumors.
1.10.4 The testis
The two primary functions of the testis are
the production of male gametes by a
process of spermatogenesis and synthesis
of testosterone, a major male sex
hormone. The first stage in mouse testis
development is the initiation of the
primary testis cord formation from
genital ridges at approximately E12
(Tilmann and Capel, 1999). The gonadal
sex is determined by the SRY gene located
in the sex determining region of the Y-
chromosome. Testis-determining factor
(TDF) encoded by the Sry gene is
responsible for the testicular
development. In addition, proper
signaling via insulin receptors has been
shown to directly influence the expression
of the Sry gene in mice, as XY mice
deficient for all three insulin and insulin
growth factor receptors develop ovaries
and a complete female phenotype (Nef et
al., 2003).  The primordial germ cells
(PGC) migrate from the allantois along
the hindgut endoderm to the genital
ridges where they are surrounded by the
primary sex cords. If the embryo contains
one X and one Y chromosome the sex
cords continue to proliferate and fuse to
form a network of internal sex cords,
loose contact with the surface epithelium
and become surrounded by a thick
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extracellular matrix, the tunica albuginea.
The primary testis cords are composed of
germ cells and precursor Sertoli cells
which are surrounded by smooth muscle
cells. Under hormonal influence of TDF
and subsequent testosterone, these cords
differentiate into seminiferous tubules,
rete testis and septa separating the
seminiferous tubules. The PGCs
differentiate into gonocytes which are
centrally located within the seminiferous
tubules. The gonocytes proliferate for a
few days and are then arrested in the G
0
/
G
1
 phase of the cell cycle until birth.
Mesenchyme separating the seminiferous
tubules gives rise to Leydig (interstitial)
cells that produce testosterone which is
important for the development of the
primordium into a testis and for the
growth and differentiation of the Wolffian
ducts to male genital ducts. The Sertoli
cells within the seminiferous tubules
produce Müllerian-inhibiting factor
(MIF) which inhibits cell division of the
Müllerian ducts, thus inhibiting the
development of female reproductive
organs.
Within a week (6 days) after birth the
gonocytes resume proliferation and start
to migrate and establish contact with the
basement membrane of the seminiferous
tubules and give rise to adult type
spermatogonia (Orth et al., 1997). By
postnatal (P) day 18-20 the appearance of
secondary spermatocytes and haploid
spermatids signify the onset of
spermatogenesis. At this time, the blood-
testis barrier is formed by tight junctions
created by Sertoli cells. These junctions
divide the seminiferous tubules into two
compartments: the basal compartment
where the spermatogonia and the earliest
primary spermatocytes reside and the
adluminal compartment which contains
the more advanced secondary
spermatocytes and spermatids. An
essential role for the testis-blood barrier
is to isolate the spermatogenic cells from
the adult immune system. The initiation
and maintenance of spermatogenesis
requires the action of FSH and LH
(reviewed by Toppari and Huhtaniemi,
1999). LH induces Leydig cells to
produce testosterone which in turn
regulate spermatogenesis through Sertoli
cells, whereas FSH binds directly to
Sertoli cells and regulates
spermatogenesis by controlling the
proliferation of Sertoli cells and the
secretion of different Sertoli cell
substances like inhibin and activin, both
members of the TGF-β family (reviewed
by Cooke and Saunders, 2002). In
mammalian adult testes, sperms are
continuously produced from
spermatogonial stem cells within
seminiferous tubules by spermatogenesis.
This process consists of three phases
(reviewed by de Rooij, 2001). During the
mitotic phase, stem cells divide to give
rise both to undifferentiated stem cells
(self-renewal) and differentiated
spermatogonia that proliferate and
differentiate. The first phase takes place
in the basal compartment between the
blood-testis barrier and the basement
membrane. In the last mitotic division of
spermatogonia, the type B spermatogonia
divide by mitosis to form early primary
spermatocytes. During meiosis of
spermatocytes, the spermatocytes move
through tight junctions from the basal
compartment of the seminiferous tubules
towards the adluminal side (Lui et al.,
2003). Before the first meiotic division,
the primary spermatocytes replicate their
DNA to contain twice the number of
chromosomes (4n) and undergo
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homologous recombination. The first
meiotic division reduces the number of
chromosomes to 2n and the cells now
become secondary spermatocytes. The
secondary spermatocytes quickly enter
the second reduction division to form
the haploid spermatids. The final phase,
the spermiogenesis consists of the
morphological change of the haploid
germ cells to the mature spermatids that
are released to the lumen of the
seminiferous tubules and transported
through rete tetis to the epididymal
duct.
Spermatogenesis continues via a
cyclic process during adult life if male
spermatogonial stem cells are capable of
both self-renewal and differentiation (de
Rooij, 2001). It is assumed that
spermatogonial stem cells either renew
themselves or produce two
interconnected spermatogonia
predestined to differentiate into
spermatids (symmetrical division), or that
one stem cell can divide asymmetrically
into one stem cell and one spermatogonia
destined to differentiate. To preserve the
steady state kinetics, the ratio between
cell renewal and differentiation has to be
close to one (de Rooij, 2001). In a
situation where germ cells are severely
damaged by exposure of the testis to
irradiation or toxic substances, the
surviving stem cells initially prefer self-
renewal (van Beek et al., 1990). The
mechanism regulating the balance
between self-renewal and differentiation
has until our study remained largely
unknown. In this study we show that
GDNF determines the spermatogonial
stem cell fate decision (IV).
Spermatogenesis is a complex process
requiring not only hormonal regulation to
transfer the intracellular stimuli but also
a large number of intracellular
mechanisms that are mediated by local
cell-cell interactions. The functions of
somatic Sertoli cells in spermatogenesis
are mediated by numerous paracrine and
autocrine local factors. Being in close
contact with the developing germ cells
through desmosome-gap junctions they
nurture them and regulate their
proliferation and differentiation
(Parvinen et al., 1986; Russell et al.,
1983). Sertoli cells can also interact
physically and chemically through
paracrine factors with the somatic Leydig
cells and the peritubular myoid cells in the
interstitial space. Recent evidence from
transgenic or gene knockout mice
suggests that distinct growth factors play
crucial roles in different aspects of
spermatogenesis. Reduction of
circulating epidermal growth factor
(EGF) through removal of salivary gland
in rodents reduces spermatogenesis and
sperm count (Tsutsumi et al., 1986).
However, transgenic mice over-
expressing EGF showed the same testis
phenotype, suggesting that the proper
levels of EGF expression is important for
completion of spermatogenesis (Wong et
al., 2000). Targeted mutagenesis of the
gene coding for bone morphogenic
protein 8b (BMP8b) causes male
infertility, whereas the homozygous
Bmp8a mice show a normal initiation of
spermatogenesis but a degeneration of
germ cells in adult homozygous males
(Zhao et al., 1998). Analysis of mice with
naturally occurring mutations in the genes
encoding for stem cell factor (SCF) and
its receptor c-Kit have implicated that
these proteins are crucial for primordial
germ cell migration and survival, and in
spermatogonial differentiation, survival
and adhesion (reviewed by Sette et al.,
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2000). Several studies indicate that the
CSF/c-Kit system is important for the
continuing differentiation of early
undifferentiated spermatogonia (reviewed
by de Rooij, 2001). SCF is produced by
Sertoli cells and its receptor c-Kit is
temporally upregulated at 6-7 days
postnatum (dpn) in early differentiating
spermatogonia (Schrans-Stassen et al.,
1999). FSH has been reported to increase
SCF mRNA in Sertoli cells (Rossi et al.,
1993). Recently, BMP4 (bone
morphogenetic protein 4) which is
produced by Sertoli cells very early in the
postnatal life has been shown to regulate
early spermatogonia differentiation and
proliferation through its receptors in
spermatogonia and to upregulate the
expression of c-Kit (Pellegrini et al.,
2003). Thus, FSH and many paracrine
factors produced by Sertoli cells
contribute to the complex regulation of
spermatogenesis. However, little is known
about the factors involved in
spermatogonial stem cell renewal.
Several studies  (IV) have shown that
GDNF and its receptors are produced by
distinct cell types in the testis. GDNF is
expressed by the Sertoli cells and Gfra1
and Ret by spermatogonia in prenatal and
early postnatal testes (Hellmich et al.,
1996; Hu et al., 1999; Golden et al., 1999;
Trupp et al., 1995; Viglietto et al., 2000).
GDNF has been shown to stimulate
postnatal germ cell proliferation
(Viglietto et al., 2000) and together with
FSH stimulate the proliferation of Sertoli
cells (Hu et al., 1999). FSH also
stimulates GDNF expression in Sertoli
cells and promotes spermatogonial
proliferation (Tadokoro et al., 2002).
Although NRTN and Gfra2 are highly
expressed in the postnatal testis (Baloh et
al., 1997; Golden et al., 1999; Viglietto et
al., 2000), no testis phenotype has been
found in NRTN- and GFRα2-deficient
mice. However, transgenic mice
overexpressing NRTN in the testis show
a transient disruption of spermatogenesis
(Meng et al., 2001b).
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2. AIMS OF THIS STUDY
The aims of this thesis were to characterize mammalian GFRα4 and to study its
biological roles in mouse and human. Another aim was to generate transgenic GDNF-
overexpressing mice and study the biological consequences for the GDNF gene dosage
primarily in testis.
The specific aims were:
• To characterize the mammalian receptors for PSPN
• To reveal sites of Gfra4-expression in human and mouse
• To study the features of GFRα4 in vitro
• To study the in vivo roles for GFRá4 by creating GFRá4-deficient mice
• To produce mice over-expressing GDNF
• To study the GDNF gene dosage effect  in spermatogenesis
Aims of this study
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3. MATERIALS AND METHODS
Most of the methods and materials used
in this work have been described in detail
in the original articles (Table 4).
3.1 Generation of the GFRá4-deficient
mice
A mouse BAC (Bacterial Artif icial
Chromosome) clone 389B9, a gift from
Dr. Gunn (Stanford, California)
containing the full coding region of
mouse Gfra4 gene, was digested with
XbaI and approximately 8 kb fragments
were isolated from agarose gel and cloned
into XbaI-opened CIP-treated pGEM11f+
vector. Gfra4 positive clones were
screened by colony hybridization. A
chromosomal region covering exons 2-5
of Gfra4 (1440 bp) was replaced by a 1.6
kb PGKneo cassette (Neomycin
resistance gene under the
phosphoglycerate kinase promoter). The
targeting vector was linearized and
electroporated into R1 embryonic stem
Table 4. List of methods used in this work (articles I-IV and unpublished results).
Method Reference or reagent Used in  
RACE cloning Marathon-Ready cDNA (Clontech),   
GeneRacer Kit (Invitrogen) 
I, II 
RNA isolation    
Human blood RNA  
Human total RNA  
Human thyroid tumors 
Trizol reagent (Life Technologies)  
RNAwiz (Ambion)  
QIAamp (Qiagen)  
Human Total RNA Panels I-IV (Clontech)  
Ultraspec-II (Biotecx Laboratories, Inc.) 
I, IV 
II, III
II
II
II
Reverse transcription SuperscriptII-III (Life Technologies) I, II, III 
PCR GC-rich PCR-kit (Roche)  
DynazymeII (Finnzymes)  
Expand Long Template PCR system (Roche)  
Expand High Fidelity PCR system (Roche) 
I, II, III
I, II, III
II
I, II 
PCR cloning  TOPO TA PCR cloning system (Invitrogen) I, II 
Sequencing ALF, Pharmacia or ABI Prism 377XL, DMSO 5-
10% (DNA sequencing facility, Institute of 
Biotechnology) 
I, II, IV 
Northern blot hybridization Sambrook and Russell, 2001 I, IV 
Southern blot hybridization Sambrook and Russell, 2001 III, IV 
Colony hybridization Sambrook and Russell, 2001 III 
In situ hybridization Rossi et al., 1999; Kokaia et al., 1999 I, II, III, 
IV
RNase protection analysis RPAII kit (Ambion), Timmusk et al., 1993  
Immunohistochemistry See below  I, III, IV 
Cell transfections  Fugene6 (Roche),  Lipofectamine 2000 ( Invitrogen) II 
125I PSPN binding assays Laurikainen et al., 2000 II 
Chemical cross-linking Suvanto et al., 1997 II 
Ret phosphorylation assay Suvanto et al., 1997 II 
Immunoprecipitation Protein A and G Sepharose (Amersham) II, IV 
Neural microinjection Hamnér et al., 2001 II 
Oocyte microinjection for transgene 
production 
Hogan et al., 1994 IV 
ES cell work, morula aggregation Papaioannou and Johnson, 2000 III 
Calcitonin measurement Rat calcitonin IRMA kit (Immunotopics) III 
Cell proliferation assay BrdU (Amersham) IV 
In situ cell death assay ApoTag (Intergen) IV 
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cells, selected with G418 and screened by
southern blot analysis. Chimeras
produced by morula aggregation
(Papaioannou and Johnson, 2000) and the
mutant Gfra4 allele was transferred into
both C57BL/6/6JOlaHsd and 129/SvHsd
mouse backgrounds by backcrossing for
at least f ive generations. Resulting
offspring was genotyped from tail DNA
by PCR using primers 5´-CGA TTC GCA
GCG CAT CGC CTT C-3´, 5´-ATA CAA
GCC TTT GAC AGC TTG C-3´ and 5´-
TGG ACA AGA TGC CTA CTG ACG-
3´. In most experiments, we used F1
hybrid wild-type and GFRá4-KO
littermates obtained from inter-crosses of
the congenic heterozygous parents. F1
heterozygous hybrid GFRá4-KO mice
were crossed with RetMEN2B knock-in mice
in a mixed (129/terSV, C57BL/6J, FVB/
N) background (Smith-Hicks et al., 2000)
to generate GFRá4/RETMEN2B-
heterozygous mice. For thyroid C-cell
calcitonin antibody staining and C-cell
counting double homozygous mutant
mice for Gfra4-/- and Ret MEN2B/MEN2B and
control mice were obtained from inter-
crosses of the heterozygous mice.
3.2 Generation of the hGDNF
transgenic mice
The full-length human cDNA for GDNF
(GenBank Accession No. L15306) was
cloned into the XbaI site of the eukaryotic
expression vector pEFBos, directed to
express the transgene under a testis
specif ic human translation elongation
factor 1 á (EF-1á) promoter (Furuchi et
al., 1996; Mizushima and Nagata, 1990).
The resulting construct was sequenced
and expression of human GDNF protein
was verified by expressing the transgene
in COS7 cells followed by western blot
analysis with GDNF antibodies. A PvuI-
HindIII fragment of the construct
containing the EF-1á promoter, the
hGDNF insert, and the polyadenylation
site, was injected into the pronuclei of
newly fertilized FVB mouse eggs to
produce the transgenic mice. Southern
blot analysis using the human GDNF as
a probe was used to analyze the founder
mice. The transgenic offspring were
genotyped from tail DNA by PCR using
human specific GDNF forward primer 5´-
TGT CGT GGC TGT CTG CCT GGT
GC-3´ and reverse primer 5´-AAG GCG
ATG GGT CTG CAA CAT GCC-3´. Four
founder lines with different transgene
copy numbers were used in this study.
Whereas the phenotypic effect can be
different in each mouse backround strain,
the GDNF-transgenic mice were
backcrossed to a NMRI mouse strain.
3.3 In situ hybridization
Radioactive in situ hybridization was
performed as described (Kokaia et al.,
1999). Antisense and sense cRNA probes
(Table 5) were synthesized using
appropriate RNA polymerases and 35S-
labelled UTP. Hybridization was
performed in 52°C overnight, slides were
rinsed to high stringency and treated with
RNaseA. Thereafter the slides were
dehydrated, air dried and dipped in NTB-
2 emulsion (Kodak), exposed for 1-4
weeks and developed. The sections were
counterstained by haematoxylin and
photographed with an Olympus AX70
Provis microscope (Olympus Optical Co.,
Japan) equipped with a SenSys CCD
camera (Photometrics Ltd.). The images
were processed using Image Pro Plus 4.0
(MediaCybernetics) or Adobe PhotoShop
(4.0-6.0) software.
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Probe Size Nucleotides Vector Accession Used in 
Mouse Gfra4 3´EST 497 bp 1-497 pT7T3 AA823200 I, III 
Mouse Gfra4 5´exon1a 127 bp 1-5, 122 bp 5´UTR pCRII AJ276870 IV 
Mouse Gfra1 777 bp 1-777 pT7T3 AF012811 I, III, IV 
Rat Gfra2 2002 bp 1-2002 pBS AF003825 III 
Mouse Gfra3 1193 bp 95-1288 pCDNA3 NM_010280 I, III 
Mouse Ret  646 bp 2534-3217 pBS X67812 I, III 
Mouse Gfra4 RPA 460 bp 95-555 pCRII AJ276870 I 
Mouse Pspn 471 bp 1-471 pCDNA3 NM_008954 Unpubl. 
Mouse Gdnf 328 bp Exon 3 pCRII U36449 IV 
Human GFRA1 379 bp 491-870 pGEM-T AF042080 II 
Human GFRA2 279 bp 148-427 pGEM-T U93703 II 
Human GFRA3 629 bp 574-1203 pGEM-T NM001496 II 
Human GFRA4 5´probe 206 bp 1-150+56 bp 5´UTR pCR2.1 AJ291673 II 
Human RET 281 bp 833-1114 pGEM-T X12949 II 
Human GDNF 636 bp 1-636 pCRII L15306 IV 
3.4 Immunohistochemistry
For thyroid and adrenal histology,
anesthesized mice were perfused
transcardially with 4% paraformaldehyde
(PFA) in PBS or Bouin´s solution. Those
that were perfused with Bouin´s solution
were postfixed for 12 h and washed for
2-3 days with PBS before processing into
paraffin, serially sectioned at 10 ìm and
stained with primary antibody against
calcitonin (Santa Cruz). For
immunofluorescence staining, sections
were stained with Cy2-conjugated
secondary antibody (Jackson
Laboratories).
Table 5. List of probes used for in situ, northern blot, southern blot, colony hybridization
and RNase protection assay
For histology on testes and
epididymides, freshly dissected tissues were
fixed in Bouin´s solution or 4%
paraformaldehyde for 2-24 hours,
depending on the size of the biopsy.
Thereafter the tissue was dehydrated and
processed in paraffin, cut at 5-7 ìm and
stained with haematoxylin/eosin. The
deparaffinized sections were incubated over
night with primary antibodies diluted
according to Table 6. Following washes with
PBS and incubation with secondary IgG
antibody, standard biotin-streptavidin-
peroxidase labeling was performed
according to manufacturer´s instructions
(Vector Laboratories, Inc., CA).
Table 6. List of primary antibodies used in immunoprecipitation or immunohistochemistry
* Used in immunoprecipitation, ** used in western blotting.
Antibody/Antigen Host Source/Reference Dilution Used in
Calcitonin Goat/polyclonal Santa Cruz, CA. 1:500 I 
Calcitonin Rabbit/polyclonal Oncogene 1:500 III 
Calcitonin Rabbit/polyclonal DAKO 1:500 Unpub. 
RET C-19 Rabbit/polyclonal Santa Cruz, CA. 1 µg/ml IP* II 
Agarose conjugated
phosphotyrosine 
Mouse/monoclonal 4G10, Upstate  30 µl/ml IP* II 
EE2 Rat/monoclonal Koshimizu et al., 1995 Gift 
from Dr. Y. Nishimune 
1:200 IV 
GATA1 Rat/monoclonal Santa Cruz, CA. 1:50 IV 
c-Kit Rabbit/polyclonal Santa Cruz, CA. 1:200 IV 
GDNF Rabbit/polyclonal Santa Cruz, CA. 1:500 
1:1000 W**   
IV
GDNF Rabbit/polyclonal R&D Systems 1µg/ml IP*     IV 
c-Ret Rabbit/polyclonal IBL, Fujioka, Japan 1:500 IV 
Materials and methods
43
4. RESULTS AND DISCUSSION
4.1 Mammalian GFRA4 mRNAs
encode for receptors lacking the
first Cys-rich domain found in
other GFRα receptors (I, II)
A putative mouse Gfra4 locus was
reported in an approximately 48 kb BAC
genomic sequence near the mouse
mahogany locus (Gunn et al., 1999). From
this raw genomic sequence, we identified
by BLAST analysis putative Gfra4 exon
sequences homologous to other Gfra
receptor genes and identif ied three
expressed sequence tags (ESTs) from the
public database that partially matched the
3´ exons of the Gfra4 locus. We
performed in situ hybridization analysis
of newborn and adult mouse sections with
one of these ESTs (GenBank Accession
No. AA823200). From this initial
information of Gfra4 tissue expression,
RACE cloning and reverse transcriptase
(RT)-PCR of Gfra4 cDNA from various
tissues were used to identify the 5´and
3´sequences and splice variants of Gfra4
mRNA. The mouse Gfra4 gene was found
to contain 6 exons with 2 alternative
exons (1a and 1b) encoding two GFRα4
alternative signal sequences (I). Gfra4
transcripts with exon 1a were obtained
from mouse thyroid but not from brain or
testis. Exon 1a was predicted to encode
for a prototypic strong signal sequence,
whereas the exon 1b signal sequence is
weak, suggesting that proteins encoded by
signal 1b remain in the cytoplasm.
Alternative splicing of exon 6 gave rise
to transcripts encoding for putative GPI-
linked or transmembrane Gfrα4 proteins.
Expression of full-length Gfra4 mRNA
(780 bp) containing the exon 1a and the
GPI-tail (GenBank Accession No.
AJ276870) (Fig. 5A), was detected in the
thyroid gland of embryonic, young and
adult mice ((I) and unpublished results),
in the juvenile (4 wk) and adult pituitary
and in the juvenile adrenal gland (I). The
full-length Gfra4 encoding for the
transmembrane GFRα4 protein (879 bp,
GenBank Accession No. AJ276871) (Fig.
5A) was also detected in thyroid, in
adrenal and in pituitary glands. Semi-
quantitative RT-PCR analysis using
primers that amplify the full-length Gfra4
mRNAs suggests that the relative
expression of the GPI-anchored and
transmembrane forms is rather similar
between newborn, juvenile and adult
thyroid (unpublished results), in contrast
to RT-PCR using primers recognizing
only the 3´end of the transcript (I).
Additionally, a full-length transcript
containing the small 53 bp intron was
found in thyroid, adrenal and pituitary
glands. This transcript was predicted to
encode for a small putative secreted
protein, as intron inclusion resulted in
frame-shift with a premature stop codon
in exon 3 (GenBank Accession No.
AJ276872) (Fig. 5A). However, as the
premature stop codon is located more
than 50 nucleotides upstream of the last
exon-exon junction of the full-length
Gfra4 mRNA, the mRNA for the putative
secreted isoform is likely to be degraded
by nonsense mediated decay (NMD), a
recently identified surveillance
mechanism that selectively degrades
nonsense mRNAs (Lewis et al., 2003;
Singh and Lykke-Andersen, 2003).
All transcripts analyzed from testis
and brain contained a small 53 bp intron
between exon 2 and exon 3 but lacked the
sequence encoding for a putative signal
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peptide which suggests an involvement of
tissue-specific regulatory elements in the
Gfra4 promoter.
Alternative splicing increases the
diversity of proteins produced by a single
gene. It is estimated that alternative
splicing occurs in more than one third of
all pre-mRNAs of human genes (reviewed
by Lou and Gagel, 2001).  The 3´donor
splice site sequence in the short 53-bp
intron between exons 2 and 3 of mouse
Gfra4 was found to be weak with a
suboptimal 3´polypyrimidine tract and
branchpoint sequence (Lou and Gagel,
1998). Weak splice sites are typically
found at alternatively spliced sites. For
example, the calcitonin/CGRP gene
contains six exons and differential
splicing of the pre-mRNA gives rise to
either calcitonin (CT, exons 1-4) mRNA
in thyroid C-cells or calcitonin gene-
related peptide (CGRPα, exons 1-3 and
5-6) mRNA in neurons. In the CT/CGRP
pre-mRNA, a weak pseudo 3´splice with
a non-canonical branchpoint nucleotide
and a short stretch of purine-interrupted
polypyrimidine tract were found in the
intron preceding exon 4 and a weak
polyadenylation signal was found in the
3´UTR (Lou et al., 1995; Lou and Gagel,
1998). Normal RNA splicing factors do
not recognize these weak sequences and
Figure 5. Structure of the mouse (A) and human (B) GFRA4 genes, splice forms and
GFRá4 protein variants. Mouse and human GFRA4 transcripts are alternatively spliced
generating different GFRá4 variants, including putative GPI-linked and transmembrane (TM)
variants. Asteriks denote stop codons. Transcripts in brackets contain premature stop codons
and are probably subjected to nonsense-mediated mRNA decay. Putative N-glycosylation sites
are indicated (Y).
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additional factors are required to
recognize these weak sites. Recently,
exonic splice enhancer elements (ESE)
have been identified in exon 4 of the CT-
gene, that upon binding of two splicing
proteins, SRp55 and human transformer
β, increase CT splicing in vitro (Tran and
Roesser, 2003; Tran et al., 2003). A splice
regulator (CSR) isolated from rat brain
has in vitro been demonstrated to bind
specifically to the ESE element in brain
and thus inhibit the CT-specific splicing
in neurons (Coleman et al., 2003). Other
sequence-specific splicing elements and
factors are presumably used for
alternative splicing of Gfra4 pre-mRNA
in endocrine cells versus brain, since the
consensus sequence for ESE found in
exon 4 of the CT-gene was not found in
mouse or human GFRA4 genes
(unpublished data).
The GPI-linked and TM GFRα4
proteins have predicted molecular
weights of 26 kDa and 30 kDa,
respectively and contain one putative N-
glycosylation site at position 184.  The
mammalian GFRα4 proteins are
predicted to form a two domain (D2-D3)
structure with 20 conserved cysteines in
the same relative spacing as in other
GFRα-receptors (Airaksinen et al., 1999).
These domains contain highly conserved
sequences homologous to the α-helix
structures found in D3 of rat GFRα1,
interrupted with less conserved loop
regions found in GFRα1 (Leppänen et al.,
2004) (Fig. 6). However, the mammalian
Gfra4 gene lacks the exons that encode
for the first cysteine rich domain (D1)
found in other GFRα receptors.
Interestingly, isoforms lacking D1 are
produced in many tissues by alternative
Figure 6. (A) Crystal structure of rat GFRá1 domain 3 shown as a ribbon diagram. á-
helices are shown as coils, disulfide bridges (dsb-1-5) are numbered from 1-5. Modified from
(Leppänen et al., 2004) with permission, from the EMBO journal, © 2004 European Molecular
Biology Organization.
(B) Electrostatic potential surface representation of the proposed putative two-domain
model for human GFRá4. Potential PSPN binding sites marked by arrows according to
conserved binding sites for GDNF to GFRá1. By permission and courtesy of V.-M. Leppänen
(2004).
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splicing of Gfra2 pre-mRNA (Dolatshad
et al., 2002; Too, 2003; Wong and Too,
1998; Wong et al., 2002).
 The amino acids in domain D2 of
GFRα1 known to be responsible for
GDNF binding (Phe213, Arg 224, Arg225
and Ile229) (Eketjäll et al., 1999;
Leppänen et al., 2004) were also
conserved in the corresponding domain
(D2) of GFRα4 with a hydrophobic
amino acid Phe at the position
corresponding to Ile229 in Gfrα1
(Leppänen et al., 2004). Furthermore, the
loop1 in D2 is longer in mouse GFRα4
(14 residues) compared to mouse GFRα1
(8 residues), GFRα2 (9 residues) and
GFRα3 (4 residues), which may reflect
allosteric positioning of D2 relative to D3
and thus ligand binding (Fig. 6). The
region between D3 and the GPI-binding/
cleavage site is shorter in GFRα4 (9
residues) compared to mouse GFRα1 (87
residues) and GFRα2 (90 residues) and
chicken GFRα4 (67 residues), which may
reflect differencies in the interaction
between GFRα4 versus GFRα1/GFRα2
to RET.
Mouse Gfra4 gene sequence data was
used to characterize the human GFRA4
gene and transcripts (II). As in mouse, the
human GFRA4 gene contains 6 exons
(Fig. 5B). A putative strong signal
sequence showing high homology to
mouse signal sequence 1a was found in
human. However, no alternative signal
sequence corresponding to exon 1b was
found among human thyroid 5´RACE
clones and no homologous sequence to
mouse exon 1b is present in the GFRA4
genomic sequence. Alternative splicing of
GFRA4 mRNA in human thyroid results
in transcripts which encode for two GPI-
linked and two putative soluble proteins.
The short introns between GFRA4 exon
2 and exon 3, and between exon 3 and
exon 4 contain weak or pseudo splice sites
like in mouse Gfra4 gene. Splicing of all
introns in the GFRA4 pre-mRNA, gives
rise to the GFRα4a protein (GenBank
Accession No. AJ291673) (290 amino
acids, Fig. 5B) with a predicted N-
glycosylation site at position 178 and a
stretch of hydrophobic amino acids in the
C-terminus preceded by a hydrophilic
linker region consistent with a GPI-
linkage anchor (Udenfriend and
Kodukula, 1995). The amino acid identity
between mouse and human GFRα4a is
79%. Translation of GFRA4b mRNA in
which the 79 bp intron is retained between
exon 2 and exon 3, results in a protein that
differs from GFRα4a in the N-terminal
part of domain D3 (GenBank Accession
No. AJ291674) (Fig. 5B). The globular
domain structure of D3 is disrupted in
GFRα4b by an additional proline- and
glycine rich loop in the N-terminal part
of domain D3, while two of the α-helical
structures (α2 and α3) and two of the
cysteine bridges (dsb-3 and dsb-4) are
missing as compared to the determined
GFRα1 D3 structure (Leppänen et al.,
2004), making the D3 structure in
GFRα4b different than D3 in GFRα4a.
GFRA4 transcripts, that retain both intron
2 and intron 3 (Accession No. AJ291675)
or just intron 3 (unpublished data) code
for putative soluble proteins with
premature stop codons. As discussed with
mouse Gfra4, these transcripts are
susceptible to nonsense mediated RNA
decay.
After completion of the study on
mouse (I) and human GFRα4 (II), Gfra4
cDNAs encoding for putative GPI-linked
and soluble receptors were cloned from
rat brain (Masure et al., 2000). The rat
Gfra4 gene was shown to contain 6 exons
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as in mouse and human. The reported
signal sequence in rat GFRα4
corresponded to the weak signal sequence
encoded by exon 1b in mouse Gfra4.
However, we identified by 5´RACE from
rat thyroid a prototypic signal sequence
for rat GFRα4 that shows high homology
to the signal sequences encoded by the
mouse Gfra4 exon 1a (76%) and by
human GFRA4 exon 1 (67%). The rat
GFRα4 showed 89% identity with the
mouse GFRα4-GPI and 80% identity
with the human GFRα4a.
4.2 The mammalian GFRα4 is the
functional receptor for PSPN (II)
To study whether the mammalian GFRα4
receptor binds PSPN, a neuroblastoma
cell line, Neuro-2a, expressing human
GFRα4a and endogenous Ret was used in
displacement binding experiments. Low
concentrations of PSPN (~1 nM)
effectively displaced 125I- PSPN from the
receptor, whereas not even high levels of
GDNF (up to 300 nM), NRTN (up to 200
nM) or ARTN (up to 200 nM) were able
to displace the bound 125I-PSPN from the
GFRα4-receptor. In the presence of Ret,
PSPN binds to human GFRα4a with a
dissociation constant (K
d
) of ~100 pM,
which is similar to the binding affinities
reported for GFRα1, GFRα2 and GFRα3
and their cognate ligands (Baloh et al.,
1998b; Klein et al., 1997; Trupp et al.,
1998). The reported equilibrium
dissociation constant for PSPN binding to
rat GFRα4 (K
d
 ~6 nM) (Masure et al.,
2000) is more than 50 times higher than
the K
d
 for human GFRα4 that we
determined. This probably reflects the
nature of the rat GFRα4 fusion protein
created by using a human signal sequence
together with the rat coding sequence and
an IgG-Fc domain. Furthermore, the
reported binding affinity of mouse PSPN
to chicken GFRα4 (K
d
~1 nM) (Enokido
et al., 1998) is also lower than found here,
which might be due to the species
difference in the PSPN and GFRα4
structure.
Cross-linking studies with 125I-PSPN
in cell lines expressing human GFRα4a
revealed that PSPN could bind to human
GFRα4a either alone or together with
RET and that excess amounts of
unlabelled PSPN reduce the levels of 125I-
PSPN bound to GFRα4/Ret.
Furthermore, 125I-PSPN cross-linked to
GFRα4 and Ret in Neuro2a cells
immunoprecipitated with Ret antibodies,
suggesting interaction with PSPN,
GFRα4 and Ret ((II), and Yang et al.,
2004). These data are consistent with the
model proposed by Jing and co-workers
that the GFRα receptor first binds to the
preferred ligand and that the ligand-
GFRα receptor complex subsequently
binds to Ret (Jing et al., 1996). However,
these data do not rule out the possibility
that a GFRα4 and Ret might be pre-
associated before PSPN binding as
suggested by an alternative model
(Sanicola et al., 1997). Treatment of cells
expressing GFRα4a, with
phosphoinositide-specific phospholipase
C (PI-PLC) after cross-linking reduced
the levels of cross-linked complexes,
confirming that the GFRα4a receptor is
linked to the cell membrane by a GPI-
anchor.
To determine whether PSPN could
induce Ret autophosphorylation through
GFRα4, hGFRα4/Neuro-2a cells were
treated with different doses of PSPN and
the levels of autophosporylated Ret were
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shown by Ret staining after precipitation
with phosphotyrosine antibody. In the
presence of GFRα4, low levels of PSPN
(0.1 ng/ml) rapidly (10 min) induced Ret
autophosphorylation, whereas no Ret
phosphorylation was detected in mock-
transfected Ret-expressing cells.
Moreover, we also demonstrated that
PSPN can promote the survival of
cultured mouse SCG neurons injected
with expression vectors encoding for
mouse Gfra4-GPI or human GFRA4a and
RET. No survival promoting effect was
seen when PSPN was added to either Ret
or mock-injected neurons. Introduction of
Gfra4 alone was already sufficient to
confer a PSPN promoting survival effect,
probably due to endogenous expression of
Ret.
Displacement binding and cross-
linking studies with the mouse
transmembrane GFRα4 isoform revealed
a much weaker affinity for PSPN binding
than for the GPI-anchored isoform (Yang
et al., 2003). Cross-linking studies
indicated that 125I-PSPN did not bind to
human GFRα4b in the presence or
absence of Ret (unpublished data). This
is consistent with the predicted disrupted
secondary structure of the region
corresponding to D3 in GFRα4b (See
chapter 4.1). It remains unclear if
GFRα4-TM or hGFRα4b can bind RET.
Thus the functional roles for these
putative alternative isoforms of mouse
and human GFRα4 remain elusive.
However, it is tempting to speculate that
the mouse transmembrane GFRα4 and
human GFRα4b isoforms may act as
dominant negative forms of the receptors,
or in fine tuning the function of the PSPN
binding isoforms.
4.3 Tissue-specific splicing produces
mRNA encoding for functional
GFRα4 only in mouse and human
endocrine tissues (I, II, III)
4.3.1 mRNA encoding for functional
GFRα4 is not present in the
normal mouse and human
nervous system
In situ hybridization and northern blot
analysis of Gfra4 mRNA in embryonic
and adult mouse showed relatively high
levels of Gfra4 mRNA expression in
neurons of the adult and newborn mouse
forebrain including cerebral cortex and
hippocampus. Lower levels of Gfra4
mRNA were detected in the brainstem
including the ventral midbrain, where
Gfra4 appeared to be partially co-
localized with Ret. Gfra4 mRNA was also
detected in the spinal cord where it did not
co-localize with Ret. However, RT-PCR
and RNase protection assay revealed that
Gfra4 transcripts did not contain exons
coding for the signal sequences 1a or 1b.
Consistent with this, in situ hybridization
on brain sections from adult mouse with
a probe specific for the GFRα4 signal
sequence 1a, did not show any labeling
above background (unpublished results).
Gfra4 transcripts with yet another
alternative signal sequence might exist in
brain, but may not have been retrieved by
conventional cloning systems.
Sequencing of GFRα4 cDNA clones
required special conditions (high
concentrations of DMSO and linearized
products) presumably due to the GC-rich
nature of the Gfra4 mRNA (70%) and
possible secondary structures. Even so,
all the Gfra4 transcripts from mouse brain
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retained the intron (intron 2) that codes
for a transcript with a premature stop
codon, and which is likely to be degraded
by nonsense mediated mRNA decay (See
chapter 4.1). Unfortunately, lack of good
antibodies to GFRα4 has so far prevented
us from studying whether soluble GFRα4
is produced in vivo. In the human CNS,
no GFRA4 expression was detected from
mRNA pools of either fetal or adult brain
or in the adult spinal cord (II). Thus our
results indicate that functional GPI-
anchored GFRα4 is not produced (or
produced in very low amounts) in the
normal mouse and human CNS. This is
supported by another study that failed to
obtain the 5´end of human GFRA4 from
brain cDNA libraries (Zhou et al., 2001).
It has been reported that PSPN
can in vitro support the survival of rat
embryonic dopamine, motor and basal
forebrain cholinergic neurons (Golden et
al., 2003; Milbrandt et al., 1998; Åkerud
et al., 2002) (Table 7), which suggests that
a functional GFRα4 receptor exists in the
embryonic rat brain or that PSPN is able
to signal via a yet uncharacterized
receptor. In vivo, exogenous PSPN has
been reported to prevent the death of adult
rat DA neurons following neurotoxic
injury by 6-OHDA and to rescue rat P2
sciatic nerves from axotomy-induced
neuronal cell death (Milbrandt et al.,
1998). Moreover, PSPN produced by
PSPN-overexpressing neural stem cells
grafted to the striatum was able to protect
adult mouse dopamine neurons from
intrastriatally administered 6-OHDA
induced cell death (Åkerud et al., 2002)
(Table 7). Furthermore, exogenous and
endogenous PSPN was reported to protect
the mouse brain from experimentally
induced ischemic insult (Tomac et al.,
2002) (Table7). In these studies, it was
assumed that PSPN induced neuronal
protection and repair through GFRα4 and
Ret, although expression of full-length
GFRα4 was shown in none of these
studies. GDNF and GDNF family
receptor gene expression have been
shown to be upregulated in neurons
following insults to the nervous system,
such as kindling-induced epileptogenesis
and experimentally induced cerebral
ischemia (Arvidsson et al., 2001; Kokaia
et al., 1999).  Although, PSPN mRNA
levels were not affected after
experimentally induced focal cerebral
ischemia (Arvidsson et al., 2001) (Table
7), upregulation of Gfra4 mRNA levels in
brain insults has not been studied. Thus,
although our results indicate that
functional GFRα4 is not produced in
intact normal brain, it remains possible
that GFRα4 is upregulated in vitro and
after brain lesion in vivo. Alternatively,
PSPN may signal yet through other
receptors. One alternative receptor could
be NCAM, as PSPN has been shown to
bind NCAM in vitro (Paratcha et al.,
2003). This binding was further
potentiated in the presence of chicken
GFRα4.
In human and mouse CNS, PSPN
expression was detected in cerebellum
and in the spinal cord. In rat, low level of
Pspn has been shown to be expressed
throughout the CNS (Jaszai et al., 1998).
The expression level of PSPN in the rat
ventral midbrain and striatum has been
reported to peak before birth and at P0,
respectively and to be downregulated
postnatally to reach low levels in adult
(Åkerud et al., 2002).
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Table 7. Reported effects of exogenous persephin in vivo and in vitro.
* Gfra4 was expressed in the adult rat ventral tegmental area and in the substantia nigra pars
compacta by in situ hybridization. The Gfra4 cDNA used as probe was not described. PNS,
peripheral nervous system; CNS, central nervous system; ND, not determined; 6-OHDA, 6-
hydroxydopamine; SN, substantia nigra; DA, dopamine; MCAO, middle cerebral artery
occlusion.
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Model Species Age Gfra4
expression
Effect of exogenous PSPN  References
Cultured PNS and  
CNS neurons
6-OHDA injections 
(striatum) 
Sciatic nerve 
axotomy 
Ureteric bud  
branching  
Rat
Rat
Rat
Rat
Rat
E14
E14
Adult 
P2
E11
ND
ND
ND
ND
ND
No survival effect on 
peripheral neurons  
Survival effect on midbrain 
DA neurons and motor 
neurons (50 ng/ml) 
In vivo protection  (10 µg 
PSPN into SN) 
Survival effect (140 µg/ml) 
following lesion 
Increase in number of 
ureteric buds (0.5-1.5 µg/ml) 
Milbrandt et 
al. (1998) 
ChAT activity in 
motorneurons 
Exitotoxic motor 
neuron death  
Neurite outgrowth 
from spinal cord 
explants 
Rat
Rat
Rat
P8
P8
P8
ND
ND
ND
No increase
High dose (100 ng/ml) added 
toxicity, low dose (0.1 
ng/ml) protective against 
chronic glutamate toxicity 
No neurite outgrowth (100-
200 ng/ml) 
Bilak et al. 
(1999)
Exitotoxic motor 
neuron death 
Rat P8 ND Protective effect against 
chronic glutamate toxicity on 
motor neurons from 500 
ng/ml  
No motor neurite outgrowth 
Ho et al.
(2000)
Focal cerebral 
ischemia induced 
by MCAO  
Rat Adult ND No upregulation of PSPN
mRNA expression (in situ
hybridization)  
Arvidsson et 
al. (2001) 
Focal cerebral 
ischemia induced 
by MCAO 
Cortical cell death 
induced by 
glutamate and 
hypoxia 
Mouse  
Rat
Mouse 
Adult 
E17.5 
ND
ND
Neuroprotective activity by 
low dose of PSPN before 
ischemia (0.1 µg) 
Low dose of PSPN reduced 
intracellular calcium influx 
(5 ng/ml) and hypoxia-
induced cell death (10 pM) 
Tomac et al. 
(2002)
Cultured DA 
neurons
6-OHDA
(striatum) 
Rat
Mouse 
E14
Adult 
ND
+, in situ*
Promotes DA neurite 
outgrowth (30 ng/ml) 
Protective effect on DA 
neurons (PSPN expressed by 
grafted neural stem cells) 
Åkerud et al. 
(2002)
Basal forebrain
neurons
Rat E16 +, PCR  
(exons 4-5, 
157 bp) 
Promotes survival of basal 
cholinergic neurons 
(30-50 ng/ml) 
Golden et al. 
(2003)
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Peripheral ganglia studied including
newborn and adult dorsal root ganglia,
trigeminal ganglia, superior cervical
ganglia, sympathetic chain ganglia and
enteric ganglia, were positive for Gfra4
mRNA by in situ hybridization. However,
full-length Gfra4 was not detected by RT-
PCR from peripheral ganglia. Gfra4
transcripts were detected by in situ
hybridization in several other mouse
tissues, including the condensing
mesenchyme of developing limbs,
postnatal testis and embryonic kidney (I).
Nevertheless, in embryonic kidney, testis,
liver and intestine, full-length transcripts
encoding for membrane anchored GFRα4
were not produced, as assayed by RT-PCR
(unpublished results). Of 26 adult human
tissues examined only thyroid expressed
GFRA4, and of the fetal tissues examined
only fetal thyroid and adrenal gland
showed expression of GFRA4 (II, Table 8
and unpublished results), indicating a
more restricted expression of human
GFRα4 than rodent and chicken (where
Gfra4 is expressed in many tissues)
(Masure et al., 2000; Thompson et al.,
1998). Consistent with these findings, no
human ESTs for GFRA4 were found in
public databases, in contrast to several
mouse ESTs for Gfra4 (I). The chicken
and mammalian GFRα4 differ in domain
structure and expression pattern which
suggests that their biological functions are
also different. The endogenous source of
ligand for chicken GFRα4 is also unclear,
since BLAST analysis of the draft chicken
genome assembly failed to find a chicken
homolog for mammalian PSPN (III).
Furthermore, chicken GFRα4 shows only
~50% amino acid identity with the
mammalian GFRα4. This indicates a less
conserved role for PSPN/GFRα4 in
vertebrate evolution compared to GDNF/
GFRα1 and NRTN/GFRα2.
4.3.2 Full-length GFRA4 mRNA is
expressed in neuroendocrine cells
of the pituitary, thyroid, and
adrenal glands (I, II)
In the embryonic and adult mouse
pituitary, Gfra4 mRNA expression was
located to the intermediate lobe, whereas
Ret mRNA was expressed in the adjacent
neurohypophysis, suggesting the
possibility of Ret-independent signaling
of GFRα4 in pituitary.  Putative
functional isoforms of GFRα4 proteins
were produced in the mouse juvenile (4
wk) and adult pituitary with the
transmembrane GFRα4 as the dominant
form. However, GFRA4 expression was
not detected by RT-PCR in adult human
pituitary probably due to the rudimentary
nature of the pituitary intermediate lobe
in human.
In the mouse adrenal gland, Gfra4 and
Ret mRNAs were highly expressed at P0
and P8 by a subpopulation of cells that
seemed to be a subpopulation of
chromaffin cells of the adrenal medulla.
In adult adrenal medulla, Gfra4 appeared
to be evenly expressed in all cells,
whereas Ret expression was only seen in
a few cells in small clusters probably
representing sympathetic ganglion cells,
according to results by Schober et al.,
(2000) (Table 8). The majority of Gfra4
transcripts obtained by RT-PCR from
postnatal and adult mouse adrenal gland
were shown to contain the short 53 bp
intron between exon 2 and 3, encoding for
the putative soluble protein. However, a
minor fraction of Gfra4 mRNAs in mouse
adrenal gland encoded for the full-length
GPI- or TM protein. In human, full-length
GFRA4 was detected in fetal
(unpublished data) but not in adult
adrenal gland (II). Expression of mRNA
encoding for the functional correct
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spliced PSPN was detected in embryonic
and adult mouse adrenal gland and in
adult human adrenal gland, suggesting a
role for GFRα4/Ret signaling in adrenal
chromaffin cell development (II, Table 8).
Alternatively, if adrenal PSPN would be
secreted to the circulating blood, it would
be able to act on a broad range of cells/
tissues.
In mouse, Gfra4 mRNA was identified
together with Ret mRNA in the
ultimobranchial body at E12, and at E16
at the beginning of fusion with the
endothelial-derived diverticulum, and
subsequent formation of the mature
thyroid. At E18 Gfra4 was co-localized
with Ret in cells in the inner part of the
thyroid lobe, which probably represents
the parafollicular C-cells (Belluardo et al.,
1999; Tsuzuki et al., 1995). In the adult
human thyroid gland GFRA4 and RET
(consistent with previous reports,
Belluardo et al., 1999; Tsuzuki et al.,
1995) expression was detected by RT-
PCR. As in mouse, in situ hybridization
of human thyroid indicated co-
Table 8. mRNA expression of RET, GFRAs  and GFLs in selected mammalian endocrine
organs.
mRNA expression determined in this work is marked by +, whereas no expression is marked
by – and a Roman numeral (I-IV) referring to article number. Expression determined by others
is marked by a given number referred to as follows: 1Schober et al., 2000 (rat), 2Krieglstein et
al., 1996 (rat), 3Urbano et al., 2000 (rat), 4Golden et al. 1999 (mouse), 5Widenfalk et al., 1997
(mouse), 6Saland et al., 2000 (rat), 7Meng et al., 2001 (mouse), 8Viglietto et al., 2000, 9Belluardo
et al., 1999 (rat), 10Tsuzuki et al., 1995 (rat), 11Baloh et al., 1998a (human), 12 Xian et al., 1999
(rat), 13Masure et al., 1998 (human), 14Creemers et al., 2002 (mouse), 15Masure et al., 1999
(human), 16 Baloh et al., 1998b (rat). ND, not determined. Unpub., unpublished results.
Tissue Ret Gfra1 Gfra2 Gfra3 Gfra4 GDNF NRTN ARTN PSPN 
Thyroid: 
C-cells
Follicular cells 
+I, II, 9, 10 
-I, II, 9, 10 
-III, 9 
-III
-III
-III
-III
-III
+I, II, III 
-I, II, III 
-9
-9
-12
+12
+16
ND
ND
-II
ND
ND
Parathyroid -I -4 +4 ND -I, III ND ND ND ND 
Adrenal:
Medulla: 
Ganglion cells 
Chromaffin 
cells
Cortex 
+1
-1
-1
+1
-1
+1
-1
+1, 5 
+1
+11
ND
ND
ND
+I
+I
-I
-2
+2
-2
-12
+12
+12
+16
ND
ND
ND
+II,
ND
ND
ND
Pituitary: 
Anterior lobe 
Interm. lobe 
Posterior lobe 
+3
-I
+I, 3 
+3
ND
+3
ND +11
ND
ND
ND
-I
+I
-I
+3
-6
+3
+12
+12
-12
+16
ND
ND
ND
-II
ND
ND
ND
Testis:
Sertoli cells 
Spermatogonia 
Spermatocytes 
Spermatids 
Oviduct
Ovary
-IV, 8 
+IV, 8 
+14
-IV
-4
-4
-IV, 8 
+IV, 8 
-IV
-IV
-4
-4
-7
-7
+7
+7
-4
-4
+11, 13 
ND
ND
ND
ND
ND
+11, 13 
-I, unpub. 
-I, unpub. 
+I,  npub. 
-I, unpub. 
ND
ND
+IV, 7, 8 
-IV, 7, 8 
-IV, 7, 8 
-IV, 7, 8 
-4
+4
+5, 7, 8 
-7
-7
-7
+5
+4
+15, 16 
ND
ND
ND
ND
ND
+15, 16 
+II , unpub. 
ND
ND
ND
ND
ND
ND
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localization of GFRA4 and RET in thyroid
C-cells. By RT-PCR Gfra4 was expressed
in the mouse thyroid by most
developmental stages analyzed. Still, the
overall expression level of Gfra4 seemed
lower in embryonic and adult than in
neonatal and juvenile thyroid as measured
by RT-PCR (unpublished data). In human,
the two identified GPI-linked GFRA4a
and GFRA4b transcripts were expressed
in equal amounts in adult and fetal
thyroid, as shown by RT-PCR (II and
unpublished data). Strong positive signal
for Gfra4, but not for Ret, was detected
in the newborn and postnatal mouse
parathyroid gland by in situ hybridization.
However, in situ hybridization with an
exon 1a-specif ic Gfra4 probe that
recognizes the mRNA encoding for the
functional signal sequence in mouse
GFRα4 (III, Table 8) did not reveal any
signal above background in the
parathyroid gland, suggesting that
functional GFRα4 is not produced in the
parathyroid gland. In conclusion, mRNAs
encoding for functional PSPN, GFRα4, as
well as other GFLs and their receptors are
expressed in several distinct types of
endocrine tissues and cells (Table 8).
However, their roles in these tissues have
not yet been determined (but see III and
IV).
Except for the brain, adrenal gland and
testis, PSPN expression was not detected
in other mouse and human tissues,
including thyroid at any developmental
stages analyzed (I, II), raising questions
about the source of ligand for the GFRα4/
Ret signaling complex in thyroid.
Members of the neurotrophin family, such
as NGF and BDNF have been found in
circulating blood (Aloe et al., 1986;
Nakahashi et al., 2000). Unlike GDNF,
that binds strongly to heparan sulfate
proteoglycans (HSPG) in the extracellular
matrix (Barnett et al., 2002; Hamilton et
al., 2001), PSPN lacks the heparin-
binding properties and does not bind to
heparan sulphate (M. Bespalov and M.
Saarma, personal communication).  Thus
it is possible that PSPN, if secreted from,
for example, adrenal gland to the
circulating blood, might be able to act in
a hormone-like manner, binding to
GFRα4/Ret on the surface of C-cells in
the thyroid.
4.4 High expression of GFRA4 and
RET in medullary thyroid tumors
suggests roles for GFRα4 in
tumorigenesis (II)
As the RET proto-oncogene is known to
play an important role in the oncogenesis
of C-cell-derived tumors and Gfra4 was
shown to be co-expressed with Ret in
developing C-cells, expression of GFRA4
and RET mRNA was analyzed by RT-PCR
from RNA derived from human thyroid
tissue tumor samples. GFRA4 mRNAs
encoding the two GPI-linked isoforms,
GFRα4a and GFRα4b were highly
expressed in all samples derived from
medullary thyroid tumors (MTC),
whereas no expression was detected in
any of the other primary thyroid tumors
including papillary thyroid carcinoma
(PTC), follicular thyroid carcinoma
(FTC) and follicular thyroid adenoma
(FTA). Consistent with previous reports
(Nakamura et al., 1994; Santoro et al.,
1990), RET was also highly expressed by
the MTC tumors. In situ hybridization on
sections from the same tumor samples,
revealed that GFRA4 and RET were
highly and evenly expressed by virtually
all the malignant cells in the MTC
samples, indicating that the expression of
Results and discussion
54
GFRA4 is C-cell specific. In line with a
recent study that showed expression of
GFRA1 and GFRA2 in some cells of
MTC (Frisk et al., 2000) very low or
undetectable levels of GFRA1, GFRA2
and/or GFRA3 were detected in a subset
of tumor cells in some MTCs. However,
low levels of GFRA1-3 were also detected
in PTCs, FTCs and FTAs, indicating that
their expression is not specif ic to
particular thyroid tumor cell type.
Furthermore, low expression of GFRA1,
GFRA2 and GFRA3 was also detected in
the normal human thyroid. This strong
expression of GFRA4 (and not other
GFRAs) in human C-cells, suggest that
GFRα4 may be critical in the oncogenic
action of RET MEN2 that leads to initial
hyperplasia of C-cells and subsequent
MTC. On the other hand, the absence of
other GFRαs in C-cells may also be
important. GFRα-receptors could
interfere with the dimerization or/and
constitutive activation of RET mutant
receptors, and therefore inhibit tumor
formation in tissues that are not involved
in MEN2 syndromes but express RET
(Kawai et al., 2000). Even GFRα4 might
be able to suppress C-cell tumor
formation by forming signaling
complexes with RET, but it may not be
able to do so as effectively as the other
GFRα´s because of the limited amount of
PSPN available, or because GFRα4 may
be weaker than the other GFRα´s in its
suppression of RET-mediated oncogenic
activity. Thus it would be of importance
to test whether GFRα4 is able to inhibit
RET MEN2A dimerization as reported
for GFRα1. Furthermore, these
hypotheses could be tested by examining
whether tumor development is altered
when transgenic MEN2 mice are crossed
with different GFRα-deficient mice. To
test whether lack of GFRα4 could
suppress C-cell hyperplasia,
pheochromocytoma and
ganglioneuromas of the adrenal medulla
GFRα4-deficient mice (III) were crossed
with RetMEN2B knock-in mice (Smith-
Hicks et al., 2000). Preliminary data
revealed that in the thyroid of 10-month-
old double mutant mice as compared to
MEN2B-mice, the number of C-cells is
reduced (Fig. 7). This suggests a positive
effect of GFRα4 in thyroid tumor
formation or a reduced number of
calcitonin expressing cells (See chapter
4.5). Unfortunately, C-cell hyperplasia
did not develop in the 10-12-months-old
RetMEN2B/MEN2B mice in the mixed
background strain, and thus we could not
use this animal model to study the effect
of GFRα4-deficiency in MTC.
To test the possibility that mutations
in the GFRA4 gene would be found in
thyroid tumors, full-length GFRA4
Figure 7. Number of C-cells in the thyroid
of double Ret MEN2B/2B; Gfra4-/- and Ret
MEN2B/2B; Gfra4+/+ littermate mice. Lack of
GFRá4 appears to reduce the number of
calcitonin positive (CT) C-cells in the thyroid
of aged RetMEN2B/MEN2B knock-in background.
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cDNAs from eight MTC tumors, the TT
cell line and normal thyroid were
sequenced. No mutations except for some
allelic polymorphisms were found in the
coding region of the GFRA4 gene (II).
4.5 Calcitonin synthesis by C-cells is
reduced in newborn and juvenile
GFRα4-deficient thyroid (III)
The GFRα4-deficient mice produced in
this study are viable and show no obvious
defects in growth and gross behavior (III).
Basic histological analysis of CNS and
pituitary did not reveal differences
between wild type and GFRα4-deficient
mice. No structural differences were
found in the adrenal medulla, including
tyrosine hydroxylase or PNMT-
immunostaining of adrenal chromaffin
cells or their cholinergic innervation
(Hiltunen et al., 2001). However, signs of
mild testis degeneration were observed in
these mice, with significantly elevated
numbers of TUNEL positive
spermatogonia in the seminiferous
tubules (Hiltunen et al., 2001). Yet, this
defect does not have an obvious effect on
male fertility. The mechanism for the
testis phenotype remains unclear (See
chapter 4.9).
As Gfra4 is highly expressed in
thyroid C-cells, and C-cells appear to be
the only cells that clearly co-express
functional GFRα4 and Ret, we focused
our studies on the effect of GFRα4-
deficiency in the development and
function of C-cells. No differences in the
number, distribution or morphology of
the C-cells were observed between the
genotypes in newborn or adult mice. To
rule out the possibility that expression of
other GFRα-receptors might compensate
for the lack of GFRα4, in situ
hybridization was used to detect RNA for
Gfra1, Gfra2 and Gfra3 in the thyroid of
1-week-old wild-type and GFRα4-
deficient thyroids.  No expression of
Gfra1 and Gfra3 was detected in wt or
Gfra4-/- thyroid. However, Gfra2 mRNA
was detected in both wild-type and
GFRα4-deficient thyroid glands (Table
8), but immunostaining with calcitonin
and GFRα2-specific antibodies showed
that Gfra2 is not expressed in the C-cells
(III).
Ret signaling is likely to be necessary
for the early development of at least some
C-cells, as Ret-deficient mice (E18) show
a clear reduction in number of C-cells
(37%) (I). Gfra1 was shown to be co-
expressed together with Ret in the
ultimobrachial body, the structure from
where C-cells are derived, but not in
neonatal thyroid C-cells (III). Therefore
it is tempting to speculate that Ret/
GFRα1/GDNF signaling might be
important for the migration of C-cells to
the thyroid gland. To address this issue,
detailed analysis of the developing
thyroid gland of GFRα1 or GFRα1/
GFRα4 double knockout mice should be
carried out.
The physiological effect of GFRα4-
deficiency was studied in juvenile
compared to adult and newborn thyroid
by measuring thyroid calcitonin levels
using an immunoradiometric assay. The
tissue calcitonin content was significantly
reduced (by 80%) in newborn and (by
~45%) in juvenile but not in the adult
GFRα4-deficient mice compared to wild
type littermates. The reduced calcitonin
production in young GFRα4-deficient
mice, appear to correlate with the
coexpression of functional GFRα4 and
Ret in thyroid C-cells. Furthermore, the
expression levels of functional GFRα4
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and Ret seem to be higher in young mouse
thyroid C-cells than in adult ((I) and
unpublished results). Additional work is
needed to quantify the relative expression
of different GFRα4 isoforms and Ret in
mouse C-cells at different developmental
stages. In conclusion, these results
suggest that GFRα4 is not necessary for
the development of thyroid C-cells but is
required in young, and not in adult mouse
thyroid, for the synthesis of calcitonin.
Thus, our results indicate a physiological
role for GFRα4 in the production of
calcitonin in the thyroid of juvenile mice.
Recent observations have shown that
GFLs via their cognate receptors may
regulate neurotransmitter release at some
synapses (Bourque and Trudeau, 2000;
Pothos et al., 1998; Ribchester et al.,
1998; Wang et al., 2001; Yang et al.,
2001). Nevertheless, the present study is
the first to show that GFRα4 regulates
calcitonin production in C-cells. This
result further suggests that other GFRα
receptors may also regulate transmitter
production in other cells.
Our results suggest that GFRα4,
presumably via Ret signaling, helps to
regulate calcitonin synthesis, but the
mechanism remains to be studied. The
mechanisms that regulate the signal
transduction pathway leading to
calcitonin production are only partially
known. Elevated extracellular calcium
[Ca2+]
e
 activates G protein-coupled
calcium sensing receptors (CaR) on C-
cells, resulting in an upregulated
expression of the calcitonin and CaR
genes (reviewed by Brown and MacLeod,
2001; Freichel et al., 1996) presumably
through activation of the thyroid
transcription factor 1 (TTF-1) (Suzuki et
al., 1998). CaR-induced calcitonin
secretion from cultured thyroid C-cells is
triggered by the activation of PI3-Kβ and
downstream effector protein kinase Cζ
(PKCζ) via Gβγ (Liu et al., 2003). Recent
studies have shown evidence for crosstalk
between G protein-coupled receptors and
tyrosine kinase receptors in the regulation
of cell proliferation (Brown and
MacLeod, 2001). Interestingly, in cells
co-expressing the EGF receptor and CaR,
dominant negative CaR inhibited EGF
induced ERK-1 phosphorylation (McNeil
et al., 1998). Furthermore, the levels of
PKCs, including PKCζ, are upregulated
upon EGF-stimulation in f ibroblasts
expressing a chimeric EGF-receptor
consisting of a RET kinase domain
(Andreozzi et al., 2003). Thus, one
mechanism for GFRα4/Ret regulation
of calcitonin synthesis could be
synergistic activation of signaling
cascades mediated by GFRα4/Ret and
CaR. Whether PSPN is required for
calcitonin production, awaits verification
from PSPN-deficient mice (Tomac et al.,
2002). Furthermore, it might be of
importance to study whether enhanced
Ret signaling in MTC caused by
activating mutations in RET can increase
the calcitonin production in C-cells.
The calcitonin production rate in
osteoporotic women has been reported to
be reduced (Reginster et al., 1989; Tiegs
et al., 1985). Furthermore, calcitonin is
successfully used to treat hypercalcemia
and metabolic bone diseases such as
osteoporosis and Paget´s disease
reflecting high osteoclast activity
(Civitelli et al., 1988; Zaidi et al., 2002).
In humans, the functional GPI-linked
GFRα4 receptor continues to be
expressed in adult thyroid calcitonin
producing C-cells (II), which suggests
that GFRα4 signaling may control
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calcitonin production in adult humans and
thus be relevant in osteoporosis.
4.6 Expression of GDNF, Gfra1 and Ret
in wild type and GDNF-transgenic
mouse testis
Transgenic mice expressing the human
GDNF-gene were produced under the
human translation elongation factor-1 α
(eEF1A) promoter. The eEF1A gene is
known to be highly expressed in various
cell types (Wakabayashi-Ito and Nagata,
1994). Surprisingly, transgenes driven by
the eEF1a promoter in the pEFBos
construct are mainly expressed in the
testes (Furuchi et al., 1996). Accordingly,
the expression of hGDNF transgene was
detected only in the testes of the
transgenic mice analyzed by northern
blotting. Four independent transgenic
founders were analyzed with the
transgene copy number ranging from 3-
20 analyzed by southern hybridization.
The males were sterile independent of
strain background, and defects were not
found in other organs than in testis.
Transgenic mice showed signif icant
reduction of the testicular weight at 4 and
8 weeks of age. Northern blot analysis
showed high endogenous expression of
GDNF, Ret and Gfra1 mRNA in neonatal
wild type mouse testes, but the levels
were down-regulated after the f irst
postnatal weeks. In situ hybridization has
revealed that GDNF is expressed by
Sertoli cells (Trupp et al., 1995; Viglietto
et al., 2000) (Table 8). Consistent with
these results, GDNF protein was detected
in Sertoli cells by immunohistochemistry
(X. Meng, unpublished results).
Messenger RNAs for Gfra1 and Ret were
shown to be expressed by a subset of
spermatogonial cells that might include
spermatogonial stem cells (IV). However,
Ret protein detected by immunohisto-
chemistry has been reported also in early
spermatocytes (Creemers et al., 2002)
(Table 8). In hGDNF overexpressing
transgenic testis, elevated levels of human
GDNF mRNA and protein were detected
in postnatal testis. Gfra1 and Ret mRNA
levels were high in spermatogonia from
birth to adulthood in transgenic testis.
Endogenous Gdnf mRNA level was also
elevated in the transgenic testis that may
be due to the alteration of the ratio of cell
population (Sertoli/germ cell).
Sertoli cells are known to release
soluble factors regulating germ cell
differentiation (Skinner, 1991). The
distribution of GDNF and its receptors in
wild type mouse testis thus suggests that
GDNF can regulate spermatogonial cell
proliferation and differentiation by
binding to GFRα1 and Ret in a paracrine
way. However, in the transgenic GDNF-
overexpressing mouse testis, the
expression of GDNF was targeted in
spermatogonia thus acting in an autocrine
manner on the regulation of
spermatogonial proliferation and
differentiation.
4.7 High doses of GDNF lead to
spermatogonial accumulation and
testicular tumors in hGDNF-
transgenic mice (IV)
The testicular morphology of hGDNF-
transgenic mice was normal at birth but
began to display large cell clusters in the
seminiferous tubules after 2-3 weeks. The
large cell clusters expressed
spermatogonial and germ line cell
markers, but not markers for Leydig or
Sertoli cells, suggesting that the cells of
these clusters are derived from
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spermatogonia. Furthermore, they did not
express c-Kit which is a marker for
differentiating spermatogonia (Schrans-
Stassen et al., 1999), suggesting that the
cells within the clusters are
undifferentiated spermatogonia including
stem cells. In the hGDNF-overexpressing
mice the normal segmental nature of cell
proliferation was disrupted, showing
some mitotic figures in all the clusters,
but the overall proliferation rate of
spermatogonia was not enhanced. In
addition, these cells were unable to
respond properly to differentiation signals
but underwent apotosis instead of
differentiation when treated with retinoic
acid, which is known to be important for
spermatogonial differentiation (Akmal et
al., 1997). These results suggested that the
majority of cells in the clusters mainly
represent stem cells of spermatogenesis
and their differentiation pathway was
inhibited by high dose of GDNF.
Furthermore, this idea is supported by a
recent germ cell transplantation
experiment where GDNF-overexpressing
spermatogonia were transplanted to testes
devoid of endogenous spermatogonia due
to prior irradiation (Creemers et al.,
2002). The transplanted spermatogonia
formed similar clusters to those in the
young GDNF-overexpressing mice,
verifying that the undifferentiated state is
unchanged because of the high expression
of GDNF  in the host clusters. More
recent supportive data showed that mouse
testes overexpressing GDNF only in
Sertoli cells (transfected by
electroporation) developed
spermatogonial clusters similar to those
found in our GDNF-overexpressing mice.
When these clusters were transplanted to
progeny cell-deficient mouse testes,
proliferation and regeneration of normal
spermatogenesis was continued in the
absence of high GDNF levels (Yomogida
et al., 2003). This study verifies that the
transplanted cells possess the normal
stem cell property. Furthermore, FSH was
shown to induce the expression of GDNF
in Sertoli cells cultures (Tadokoro et al.,
2002) and to stimulate rat Sertoli cell
proliferation in vitro (Hu et al., 1999),
suggesting a hormonal control of
spermatogenesis conducted via the
GDNF/GFRα1/Ret system.
The undifferentiated spermatogonia in
GDNF overexpressing transgenic mice
(IV) were able to proliferate, but not
differentiate, which eventually lead to
germ cell degeneration and sterility.
Apotosis in cell clusters was increased
with the peak at week 4. At 10 weeks of
age only remnants of clusters were visible
and a rim of spermatogonia remained at
the base of atrophic seminiferous tubules.
No sperm was visible in seminiferous
tubules or the epididymis, and the somatic
cells of the seminiferous tubules were
normal as compared to wild type testes.
Bilateral (56%) and unilateral
testicular tumors frequently developed in
mice over 1 year (89%) from the dormant
spermatogonia which spread into the
interstitial tissue but did not distantly
metastasize. Interestingly, morphological
and histological analysis of the GDNF-
transgenic mouse tumors revealed many
of the characteristics found in human
classical seminomas, a common testicular
tumor in young men (Meng et al., 2001a).
They consist of homogenous round cells
with large nuclei, express germ cell
markers and are positive for placental
alkaline phosphatase. In contrast,
spermatocytic seminomas are more
heterogenous; often showing gigantic
cells derived from spermatocytes or B
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spermatogonia and usually not positive
for alkaline phosphatase staining
(Chaganti and Houldsworth, 2000). The
GDNF transgenic mouse can thus serve
as the first experimental animal model for
this tumor type. However, although
murine and human seminomatous tumors
are similar in many aspects, some
differences exist which have to be taken
into consideration when using this model.
The tumors appear in old transgenic mice
in contrast to tumors in young men, they
show no lymphocyte infiltrates that are
common in human seminomas and they
do not stain for c-Kit which is frequently
detected in human classical seminomas
(Devouassoux-Shisheboran et al., 2003;
Meng et al., 2001a).
High expression of transgenic GDNF,
and endogenous Gfra1 and Ret was
detected from tumors along with high Ret
phosphorylation (Meng et al., 2001a).
Expression of GDNF and its receptors has
also been detected in human seminomas
in contrast to non-seminomas (Viglietto
et al., 2000), which indicates that GDNF
signaling is involved in the pathogenesis
of classic seminomas. This issue could be
addressed in vitro by measuring the
proliferative effect of GDNF on a recently
Figure 8. Control of spermatogonial stem cell differentiation and renewal by GDNF
dosage. Appropriate level of GDNF controls the balance between differentiation and prolif-
eration of spermatogenic stem cells. Low dosage results in depletion of stem cells, whereas
high dosage results in depletion of differentiating spermatogonia.
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established rat spermatogonial stem cell
line (van Pelt et al., 2002) or by
overexpressing GDNF in mutant mice
with progeny-deficient testes (Tadokoro
et al., 2002).
4.8 Low doses of GDNF result in
depletion of stem cells in
heterozygous GDNF+/- mice (IV)
While mice lacking GDNF die during the
first postnatal day, most GDNF+/- mice
survive to adulthood but show
developmental renal and ENS
abnormalities probably due to
haploinsufficiency (Moore et al., 1996;
Pichel et al., 1996; Sanchez et al., 1996).
In order to reveal the role for decreased
GDNF expression in mouse testis,
histological analysis of testes from
heterozygous GDNF+/- mice (Pichel et
al., 1996) was performed. The GDNF+/-
mice survived to adulthood and were
fertile though spermatogenesis was
disturbed. Histological analysis of 5 and
8 week-old GDNF+/- testes revealed that
atrophy was detected in about half of the
seminiferous tubules but spermatids
could be observed. However, sperm cells
were observed in the epididymal ducts
and in well preserved seminiferous
tubules. In older GDNF+/- mice,
spermatogonia were depleted and cell
proliferation was reduced resulting in
Sertoli cell-only tubular segments. In
conclusion, the spermatogonia
differentiate in excess in GDNF+/- mice,
leading to depletion of undifferentiated
germ cells.
In summary, by using GDNF-
overexpression and loss-of-function
approaches we have shown in vivo that
GDNF dosage determines the cell fate
decision of spermatogonial stem cell
renewal and differentiation in mouse.
High dosage inhibits stem cell
differentiation, leading to degeneration of
tubular germ cells, whereas low dosage
leads to progressing stem cell depletion
(Sertoli-cell-only) due to the prevailing
differentiation exceeding proliferation of
stem cells (Fig. 8).
4.9 Does NRTN or PSPN have a role in
testis?
Apart from GDNF, NRTN is also
expressed by Sertoli cells and can
stimulate proliferation in Ret expressing
spermatogonia (Viglietto et al., 2000).
However, no testis phenotype has been
reported in NRTN- or GFRα2-deficient
mice (Heuckeroth et al., 1999; Rossi et
al., 1999). Yet, transgenic mice
overexpressing NRTN in testes, although
fertile, show a transient degeneration of
spermatocytes at 3-5 weeks of age in a
fraction of mice (Meng et al., 2001b),
which indicates that a proper
concentration of NRTN is needed for
differentiation of spermatocytes. Gfra2
mRNA is highly expressed by spermatids
in wild type mouse testis, whereas Nrtn
expression is upregulated in testes after
puberty. The Gfra2 transcript in postnatal
testis is smaller in size (1-2 kb) compared
to Gfra2 in somatic tissues (~4 kb) (Baloh
et al., 1997; Meng et al., 2001b). RT-PCR
and RACE-cloning revealed that the full-
length Gfra2 is expressed in embryonic
and newborn testis, whereas only
truncated Gfra2 transcripts are expressed
in adult mouse testis (unpublished
results). These transcripts lack sequences
corresponding to exons 1-4 of the Gfra2
gene which encode for the N-terminal
part of GFRα2 (signal sequence and
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domains D1 and D2). These results
suggest that the functional GFRα2
receptor is not produced in pubertal and
adult spermatocytes. The role for NRTN
produced by Sertoli cells thus remains
elusive, but may signal through GFRα1,
as the expression of Gfra1 and Ret mRNA
is downregulated but not absent from the
postnatal mouse testis (IV).
PSPN was shown to be expressed in
human and mouse adult testis by RT-PCR
(I, II). The cellular localization of PSPN
expression in testis could not be
determined because the expression levels
were beyond detection by in situ
hybridization. In adult mouse testis,
moderate levels of Gfra4 transcripts were
found in pachytene spermatocytes
(unpublished data, Table 8). Northern blot
analysis also revealed a clear Gfra4
transcript from testis that was smaller in
size (1.2 kb) than the mRNA retrieved
from thyroid (1.4 kb) (I). RT-PCR showed
aberrant splicing of the Gfra4 transcript
and 5´RACE using adult testis cDNA
resulted in short clones containing only
the transcript encoding for D3 of GFRα4
without signal sequence. Despite several
attempts, transcripts encoding for full-
length GFRα4 containing a signal
sequence were never achieved by RACE
cloning.
Many genes normally expressed in
somatic cells appear to be overexpressed
in mammalian pachytene spermatocytes
and round spermatids (reviewed by
Kleene, 2001). These transcripts differ in
size and structure from the somatic
transcripts and often use TATA-
independent spermatogenic cell-specific
transcription start sites (SCS) located
upstream or downstream the somatic start
site and alternative splicing as well as
upstream polyadenylation sites. Some of
these spermatogenic cell-altered
transcripts (SCATs) are at least partially
translationally repressed or encode for
severely truncated proteins that cannot
perform the same functions as the
proteins encoded by the same gene in
somatic cells. The role for this leaky non-
specific process in spermatocytes is
unknown, but at least some of these
truncated proteins appear to be functional.
For example, the CSC isoform of c-Kit in
round spermatids lacks its extracellular
and transmembrane domains but it may
still participate in the activation of
development of fertilized oocytes (Sette
et al., 1997). Thus, truncated mRNAs of
Gfra2 and Gfra4 in testis probably
represent SCATs and, if anything, they
might have a distinct function in testis or
in the fertilization process. It would be
necessary to confirm whether truncated
GFRα2- and GFRα4-proteins indeed
exist in spermatogenic cells.
Results and discussion
62
5. CONCLUSIONS
• Mouse and human GFRá4 receptor is smaller in size lacking the first Cys-
rich domain found in other GFRá-receptors, including chicken GFRá4. PSPN,
but not other GFLs, can bind with high affinity to the mammalian GFRá4
receptor and autophosphorylate Ret tyrosine kinase. In the presence of GFRá4
and RET, PSPN, but not other GFLs, can induce survival of cultured rat
sympathetic neurons. Thus GFRá4 is the functional PSPN receptor.
• Mammalian GFRA4 mRNA expression is restricted to endocrine cells, such
as thyroid C-cells and adrenal chromaffin cells. Tissue specific splicing of
Gfra4 pre-mRNA produces functional GFRá4 in young mouse thyroid gland.
High expression of GFRA4 together with RET in human medullary thyroid
carcinoma suggest a role for GFRá4 in tumor formation.
• Decreased calcitonin synthesis in young, but not adult GFRá4-deficient
thyroid, indicate a novel role for GFRá signaling in controlling transmitter
synthesis. This also suggests that GFRá4/Ret-signaling regulates calcium
homeostasis and may therefore be relevant in human osteoporosis.
• In testis, the ratio between stem cell renewal and differentiation is regulated
by GDNF dosage as spermatogonial stem cells are exhausted (Sertoli-cell-
only) in GDNF-deficient mice, while overproduction of GDNF leads to
clustering of spermatogonial stem cells. These mouse lines could serve as
useful tools for studying the pathogenesis of male infertility and testicular
cancers. The importance of GDNF signaling in spermatogenesis suggests that
specific molecules in the GDNF/GFRá1/Ret signaling pathway could serve
as potential targets for designing male contraceptives.
Conclusions
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